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Abstract
Generalized anxiety disorder (GAD) is a common mental health condition in the United
States and significant in causing role impairment and decreased functioning in daily life
for many patients (Ruscio et al., 2017). The American Psychiatric Association has yet
to release standardized clinical guidelines for GAD (American Psychiatric Association,
2019a). Without standardized management of GAD. providers are at risk of prescribing
benzodiazepines long-term for GAD sufferers, which is associated with many
detrimental side effects. Review of related literature provides guidance for providers
about the use of cognitive-behavioral therapy (CBT) and selective serotonin reuptake
inhibitors (SSRIs) for patients of GAD (Maust, Kales, Wiechers, Blow, & Olfson,
2016). The purpose of this research was to assess the management practices of GAD
among primary care providers in northern Mississippi. The theoretical framework for
the study was Betty Neuman's systems model. Research questions were answered

regarding the use of appropriate treatment options for GAD patients, and descriptive
statistics were used to present findings.
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CHAPTER I
Introduction: Dimensions of the Problem
Generalized Anxiety Disorder (GAD) is a common anxiety disorder affecting
approximately 18% of the American population at some point in their lifespan.
Characterized by excessive, irrational worry, GAD can be debilitating, causing role
impairment and significant comorbidities (Ruscio et ah, 2017). Patients with GAD are
increasingly turning to primary care providers (PCPs) for the management of their
anxiety symptoms (Weisberg, Beard, Moitra. Dyck, & Keller, 2014). Although there
are evidence-based studies supporting the use of certain phannacological treatments for
the disorder, the American Psychiatric Association has not published clinical guidelines
for PCPs to follow as of 2018 (American Psychiatric Association, 2019a). Without a
standardization of treatment, evidence-based practices such as cognitive-behavioral
therapy (CBT) are under-prescribed or unavailable, while the use of benzodiazepines,
which cause dependence if prescribed long-tenn, continue to be prescribed for GAD
patients in Mississippi (Mississippi Prescription Monitoring Program, 2018).
Background Information
GAD is a recognized anxiety disorder, first acknowledged in 1980 in the third
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-lII). Since
that time the diagnosis has been revised. According to the fifth and current edition of
the DSM, GAD is a diagnosis characterized by excessive, uncontrollable worry, with
the potential for physical side effects, role impainnent, and psychiatric comorbidities.
The disorder is particularly prevalent in the United States, where it is estimated that
18% of citizens experience GAD at some point in their lifetime, whether a short-term or

long-term case (Ruseio et al., 2017). Another study estimated the prevalence of all
anxiety disorders as high as 18% of the general population and at an annual cost of
more than S42 billion (Greenberg et ah. 1999). A systematic review showed that there
is a high prevalence of anxiety across the globe and anxiety disorders are increasingly
recognized as a determinant to poor health and major consumption of health sendees
dollars (Remes, Brayne. van der Linde, & Lafortune. 2016).
The implications for role impairment are of particular interest to the
consideration of GAD. This disorder can cause significant consequences for carrying
out daily activities. In a global incidence study published in 2017, half of patients who
experienced GAD for at least a year reported being unable to work or carry out normal
activities on 40 days in the preceding year. The majority of GAD patients globally have
a lifetime diagnosis (3.7%) as opposed to a 30-day (0.8%) or 12-month course (1.8%).
Given the often long-term reality of the disorder, the economic implications of missed
days of work alone should warrant attention from clinicians. Additionally, GAD is
frequently comorbid with other psychiatric conditions including major depressive
disorder (MDD) in 52.6% of lifetime cases. The comorbidity with MDD places GAD
patients at an even greater risk of role impairment. Common sociodemographic
correlates for GAD include female sex, age < 60 years old, and unmanned status
(Ruseio et al., 2017).
Despite its status as a psychiatric disorder, GAD patients are increasingly
turning to PCPs for treatment. Weisberg et al. conducted a study published in 2014
which found that half of GAD patients were using a PCP for their condition. Yet
despite the great relevance to primary care, the American Psychiatric Association has

not published clinical guidelines to standardize the treatment of GAD or related
diagnoses, such as agoraphobia or panic disorder (American Psychiatric Association,
2019a).
In spite of the lack of clinical practice guidelines from an authoritative body,
research does provide guidance to PCPs for first-line treatment of GAD. Multiple
studies have confirmed the efficacy of CBT for reducing patients" GAD symptoms.
Although effective, CBT is not always prescribed to GAD patients. This could be due
to lack of CBT centers or providers" lack of awareness of the usefulness of CBT for
GAD. Pharmacological first-line

treatment for GAD is considered to be selective

serotonin reuptake inhibitors (SSRls) according to current research (Maust et al., 2016).
Notably, SSRIs are effective in treating not only GAD but also MDD, a common
comorbidity. The extent to which PCPs prescribe SSRIs as first-line

pharmacotherapy

for GAD in the northern Mississippi region is unknown.
Although CBT and SSRIs have been established in research as first-line
treatment options for GAD, many providers prescribe benzodiazepines long-term for
patients with persistent anxiety. The use of benzodiazepines long-term is associated
with poor outcomes for patients, including falls, cognitive decline, and drug overdose.
Moreover, the drug class is noted for creating dependence and requiring increasing
amounts of the drug over time to achieve the same effect. Populations most commonly
correlated with developing dependence on benzodiazepines include the elderly and
those with chronic medical conditions. One study found that 8.7% of American adults
aged 65-80 years old were prescribed benzodiazepines over the course of a year often

for anxiety or insomnia and despite the fact that psychotherapy and alternative
medications are preferential fonns of treatment (Maust et ah, 2016).
Despite the risks involved in prescribing benzodiazepines, as of July 9. 2019.
there are currently no prescriptive guidelines for nurse practitioners in Mississippi
regarding the drug (Mississippi Board of Nursing, 2018). However, the Mississippi
State Board of Medical Licensure limits the prescription of benzodiazepines to 90 days
and should not be taken in conjunction with opioids. Patients taking both an opioid and
a benzodiazepine are to be weaned off one or both. Prescribers are furthermore required
to verify controlled substance prescriptions for these patients from the Mississippi
Prescription Monitoring Program (Mississippi State Board of Medical Licensure. 2018).
In 2017, 257,099 residents in Mississippi had at least one prescription of
benzodiazepines filled with a total of 1,254,292 benzodiazepine prescriptions filled in
that year. These figures translate to an average of 4.88 prescriptions of benzodiazepines
per patient, indicating an excess beyond the recommended duration of treatment.
Furthermore, 69,605 patients in Mississippi in 2017 filled prescriptions for both a
benzodiazepine and an opioid in the same day (Mississippi Prescription Monitoring
Program, 2018). These statistics are a local representation of a broader epidemic of
controlled substance prescription abuse in the United States as implicated in criminal
activity, substance-abuse disorders, and death due to overdose (Dineen & Dubois,
2016).
Problem Statement
The gravity of treating GAD according to evidence-based research is great.
Research has shown that the disorder is significant due to its prevalence in the

American population, its implications for role impairment and decreased functioning,
and the potential for comorbidities. Although credible research exists to direct care
PCPs give patients diagnosed with GAD. there are no firmly established treatment
guidelines. Without rigorous guidelines regarding benzodiazepines treatment in GAD,
patients are placed at risk of receiving treatment with benzodiazepines that does not
comply with contemporary research. This in turn places patients at risk for developing
dependence on benzodiazepines.

Statement of Purpose
The purpose of this research was twofold. First, the research revealed the
practices among primary care providers in northern Mississippi for treating GAD
whether psychotherapy, pharmacological, or a combination. The specific modalities of
psychotherapy and pharmacotherapy were listed. Second, the research revealed that
these management practices are consistent with contemporary evidence-based research.
If the study revealed that clinicians are not currently practicing in accordance with
current research recommendations, the need for clinical guidelines to standardize care
would be apparent. If data revealed that clinicians are already incorporating evidencebased research into their practice, this would provide a prediction of the relative ease for
PCPs to transition to standardized guidelines. The study also addressed the titration of
long-term benzodiazepines and interventions that can be used to facilitate the cessation.
According to Vicens et al. (2016), there was supporting evidence that proved the
interventions of structured intervention with follow-up visits or structured intervention
with written instructions showed a reduction in the long-term use of benzodiazepines at
12 months by up to 30%.

Significance of the Research Project
Approximately half of GAD cases are treated in the PCP setting. Therefore
knowledge of how best to manage this condition is very pertinent for PCPs (Weisberg et
ah, 2014). The provider runs the risk of discipline for not following best practice,
particularly related to the prescription of controlled substances. With increased
attention on PCPs for prescription of benzodiazepines and opioids, clinicians should
take note of imminent changes which could invite scrutiny on their practice (Dineen &
Dubois, 2016).
Without appropriate treatment of their anxiety, the patient faces risks of
continued role impairment and comorbidity with other psychological disorders. Role
impairment leads to decreased productivity at work, missed days of work, and poor
functioning in activities of daily life. Unfortunately, mismanagement of GAD can even
lead to the development of dependence on benzodiazepines, which has been proven to
be linked to a number of poor outcomes, including drug overdose, falls, and cognitive
decline (Maust et ah, 2016). With standardization of treatment for GAD according to
current research, these poor outcomes can be prevented and patients will be treated in a
way that will restore them to normal functioning.

Conceptual Framework
Betty Neuman's systems model was used as a framework for this research.
Some of the major concepts from this model include the uniqueness of the individual,
adaptation to stress, and wholistic wellness promotion. Due to these major concepts,
the systems model is frequently used to guide nursing research related to psychological

stress or dysfunction. Neuman wrote about four major assumptions pertinent to the
application of the model: person, environment, health, and nursing (Lawson, 2018).
According to the systems model, the individual has innate protection against
threats to homeostasis from two lines of resistance. The outer line of resistance is
flexible; it is the first protection against stressors and can be weakened or strengthened
by circumstances. The inner line of defense, or normal line, is built over time. The
greater the normal line of defense, the more stable the individual is against threats to
homeostasis. The nurse's role in the systems model is to prevent stress. Primary
prevention involves avoiding the stressor. Secondary prevention is intervening to
stabilize once stress has occurred. Tertiary prevention is the longer term adjustment and
active treatment following stress (Lawson, 2018).
Neuman wrote about the application of the systems model to contemporary
nursing practice in an article written in 2000, entitled Leadership-Scholarship
Integration: Using the Neuman Systems Model for 21st-century Professional Nursing
Practice. Neuman wrote that, in the context of modern healthcare, leadership and
scholarship should be considered as symbiotic rather than discrete concepts. Instead of
the traditional view regarding leadership as the practice of nursing and scholarship as
the theoretical or academic examination of nursing, Neuman proposed that the two
should be fully integrated for the best delivery of healthcare. Neuman provided three
rationales for how the systems model is ideal for joining nursing leadership with
scholarship. First, the systems model is described as proven to be applicable to a
myriad of organizational and healthcare systems. Second, the systems model facilitates
a nurturing environment which promotes stress reduction and systemic stability. Third,

the systems model is compatible with nursing shared governance which has become
prominent in healthcare organizations in the 21st century (Neuman, Newman, &
Holder, 2000).
Neuman's systems model is an appropriate selection for the current research on
GAD and management practices among primary care providers in northern Mississippi.
The systems model has been proven to be a valid framework for nursing scholarship
and is particularly helpful for research regarding anxiety or stress (Lawson, 2018).
Specifically. Neuman's concept of stressors as coming from many systems is
compatible with the definition of GAD as a condition of excessive, uncontrollable
worry, regardless of the source of worry (Ruscio et al, 2017). Neuman's emphasis on
the wholistic assessment of the patient is critical to a good understanding of how best to
treat patients with GAD. For example, the current research evaluated physiological
comorbidities with GAD that would factor in under the biological system of the
wholistic understanding of stressors on the patient. Demographic data obtained in the
current research provided an assessment of the patient's social system (Lawson. 2018).
By analyzing how healthcare providers are managing patients with the diagnosis
of GAD, insight was gained regarding the best way to identify patients with anxiety and
manage their symptoms (secondary prevention). Through effective prevention
methods, the patient's flexible line of defense was strengthened. Neuman's four
assumptions were addressed in the current research. Person is identified as patients
with a diagnosis of GAD. Health is defined as the equilibrium of all systems within the
person. Environment entails both internal and external factors influencing the patient's
homeostasis. Nursing is defined as the unique role of the healthcare professional to care

for the person with compassion and competence. Through the information gained from
the current research, primary care providers will be better informed on how to care for
patients with GAD. which will actualize Neuman's systems model for leadershipscholarship integration (Neuman et al., 2000).
Definitions of Terms
Primary Care Providers
Theoretical: According to the American Academy of Physicians, primary care
providers are licensed healthcare professionals who are trained and skilled in first
contact with patients with healthcare needs and provide continuing care for established
patients with healthcare treatment, health advocacy, or referral as appropriate
(American Academy of Family Physicians, 2019b).
Operational: Nurse practitioners, physician assistants, or physicians (MD or
DO) who provide care to patients in five primary care clinics in northern Mississippi.
Generalized Anxiety Disorder
Theoretical: According to the American Psychological Association, an anxiety
disorder in which the patient has excessive and persistent worry that affects the patient's
daily activities. This continuing worry and strife may be in association with physical
symptoms, such as restlessness, difficulty in concentration, sleeping problems,
fatigability, muscle tension, or feelings of on the edge of something bad (American
Psychiatric Association, 2009b).
Operational: A mental health concern diagnosed with the ICD-10 codes F41.1
(GAD) or F41.9 (Anxiety disorder, unspecified ) in the patient's chart or electronic
health record.

Benzodiazepine
Theoretical: A class of psychoactive drugs whose core chemical structure is the
fusion of a benzene ring and a diazepine ring. These drugs enhance the effect of the
neurotransmitter gamma-aminobutyric acid (GABA) at the GABA receptor, resulting in
sedative, hypnotic, anxiolytic, anti-convulsant. and muscle-relaxant properties
(Benzodiazepines: Uses, Side Effects, Interactions & Warnings, 2019).
Operational: A class of drugs that acts as tranquilizers and are commonly used
in the treatment of GAD F41.1 or Anxiety disorder, unspecified F41.9.
Psychotherapy
Theoretical: Therapy involves communication between patients and therapists
that is intended to help people: (1) find relief from emotional distress, as in becoming
less anxious, fearful, or depressed; (2) seek solutions to problems in their lives, such as
dealing with disappointment, grief, family issues, and job or career dissatisfaction; (3)
modify ways of thinking and acting that are preventing them from working productively
and enjoying personal relationships (American Psychiatric Association. 2019b).
Operational: Also called "talk therapy," cognitive behavior therapy or just
therapy is a process whereby psychological problems are treated through
communication and relationship factors between an individual and a trained or lay
mental health professional. For the purposes of this study, the term therapy was used in
the place of a more specific term as there was limited access to specialized forms of
psychotherapy in the region where the study took place.

Controlled Substances
Theoretical: A controlled substance is an illegal drug that can have a detrimental
eftect on a person's health and welfare, as well as many drugs that are prescribed to the
general public and sold through pharmacies and dispensaries for legitimate medical
treatment. The federal government defines a controlled substance as any of the
substances listed in the schedules of the Controlled Substance Act of 1970. The
schedules are broken down into five categories: Schedule 1. being illegal and the most
addicting, to Schedule V, being primarily preparations that only contain a limited
quantity of narcotics (Findlaw, 2018).
Operational: A Schedule IV medication, such as Valium, Ativan, Xanax, or
Klonopin, prescribed by a physician, physician assistant, or nurse practitioner for the
treatment of GAD.
Research Questions
1. Are PCPs in northern Mississippi referring patients to psychotherapy for
treatment of GAD?
2. What medications are PCPs prescribing for the treatment of GAD?
3. If PCPs are prescribing benzodiazepines to their GAD patients, are they
limiting prescriptions to 3 months?
Assumptions
The researchers assumed that information from retrospective chart review would
be informative for the research project and that electronic medical records/charts would
be organized, accessible, truthful, and up-to-date. If paper charts were used for data
collection, a further assumption was that charts would be legible.

Limitations
Multiple limitations to the research have been identified. Data were gathered
from relatively few clinics in a limited geographic area. Because of this, the sample
size was small. The small sample size and limited geographic area covered limited
generalizability of findings to the broader Mississippi or southeastern American
population. Another limitation was that since data were collected from retrospective
chart reviews, any pertinent information outside of the chart would not be discoverable
to the researchers. The data collection tool used to compile the findings was original to
this study and had not been externally validated. Another limitation of the study
concerned potential misdiagnosis of GAD. Due to prevalent comorbidity with
depression and some common symptoms, it is possible for patients to be diagnosed with
GAD who may more appropriately be diagnosed with depression. A further limitation
was that PCPs in northern Mississippi may not have adapted practice to current
Mississippi Board of Medicine mandates regarding benzodiazepine prescription in the
time period of data collection for this study.

CHAPTER II
Review of Literature
1 he current researchers evaluated the management practices of GAD among
primary care providers in northern Mississippi. After an extensive review of literature,
the following articles were selected that most represented the current evidence-based
research regarding GAD and appropriate treatment for the disorder. Betty Neuman's
systems model was used as the theoretical framework to guide the research study.
Health Promotion Model
Betty M. Neuman, RN, BSN, MS, PhD, PLC, FAAN, is known as a pioneer in
the area of nursing involvement in mental health and creator of the Neuman Systems
Model. Neuman created the model in 1970 to develop a student guide for college
students to increase awareness of patients" variables beyond the accepted medical
models of the time. Dr. Neuman's model w as first published in 1972 and has remained
relevant throughout the continuum of nursing. The model has remained true to the core
of its vision but has evolved with the times and now has a fifth edition which was
published in 2010.
The Neuman Systems Model (NSM) presents a framework that views the client
as an open system that reacts and adapts to both internal and external stressors. In the
NSM, the client may be a person, family group, community, or social entity. Clients are
viewed wholly and all variables affect the client. Neuman identified variables within
the client system: physiologic, psychological, sociocultural. developmental, and
spiritual. Neuman identified the system of the client as an open system in which the
client reacts and adapts to all stressors. The NSM also states that within the client

system, there are normal lines of defense and flexible lines of defense and all variables
are addressed in these lines of defense. Stressors within the client system are classified
as intrapersonal, interpersonal, or extrapersonal. Additionally, the model identifies
three levels of nursing interventions within the system: primary prevention, secondary
prevention, and tertiary prevention. With these levels Neurnan proposes interventions
in which primary prevention interventions strengthen the flexible line of defense,
secondary prevention restores equilibrium, and tertiary prevention prevents further
damage and maintains stability after the event. The NSM is a well-accepted framework
for nursing clinical practice, nursing education, and nursing research (Memmott. Marett,
Bott. & Duke, 2000).
The NSM is of great importance to the nursing profession as its concepts and
framework have made many contributions to nursing. The greatest potential for the
NSM is its focus on primary prevention, assessment of the client system, and
interdisciplinary care concepts. The NSM has in the past served the nursing profession
well, but with its broad and adaptable concepts the model may serve nurses well for the
future. With every evolving healthcare system of today and the future, the NSM will
help the nursing profession evolve as well (Alligood, 2018).
At the turn of the century, Neuman (in collaboration with Newman and Holder)
published an article in which the timeless nature of the NSM was applied to developing
a futuristic vision of how the nursing model will need to evolve in the 21st century. In
this article the authors set out to define the terms leadership and scholarship and
combine them for advancement of the nursing profession for the coming years. In the
article the authors stated that wholism, reliability, flexibility, and comprehensiveness

are key components tor nursing as nursing roles and responsibilities continue to expand.
The NSM framework provides a solid base for the development of leadership and
scholarship driven nursing process and provides scientific validity to their work. The
authors imply that, when leadership and scholarship are combined with a true open
system model as a base, the outcome will be nursing leadership that will support the
client-driven movement of the new century and provide quality care, improved work
situation, organizational effectiveness, and replace competition with collaboration. The
authors also identified theoretical markers in leadership and scholarship system that are
directives for using leadership knowledge and skills of scholarship. These markers
consist of the following: (a) defining boundaries, (b) identifying normal lines of
defense, (c) assessing the effects of the NSM five-client system variables in context to
weaknesses and strengths of the systems line of defense, (d) identify external and
internal stressors within the environment and their effects, (e) set realistic goals in
which best client function is to be maintained, (f) create intervention plans that are
addressing the three levels of prevention (primary, secondary, and tertiary) to wellness
maintenance, and (g) identifying a system of evaluation to confirm goal attainment or
needed additions (Alligood, 2018). The authors stated that leadership and scholarship
are dependent upon each other and are to be used as a vehicle to move forward nursing
in the coming future (Neuman, 2000).
The NSM has been utilized as a theoretical framework for many studies. In
1993 Waddell and Demi developed a study, entitled '"Effectiveness of an Intensive
Partial Hospitalization Program for Treatment of Anxiety Disorders." In this study the
authors utilized the NSM for the theoretical framework.

The authors chose the NSM

because the model acknowledges clients as being an open system and is a part of the
environment in which the client finds themselves in. In the study, Waddell and Demi
(1993) identified anxiety disorders as widespread and treatment-resistant disorders that
can be great stressors to those who are affected. This study was developed to evaluate
the effectiveness ot utilizing intensive partial hospitalization as a treatment for anxiety
disorders. The study assessed the treatment modalities of combining biological,
psychological, and social modalities in a 5-week intensive outpatient setting. The
study's hypotheses stated the following: "Fear of fear" (anticipation of a panic attack) is
significantly lower posttreatment than pretreatment; severity of impairment will be
lower posttreatment than pretreatment; and general emotional distress (any one of the
six recognized subconcepts of anxiety) is significantly lower post-treatment than
pretreatment (Waddell & Demi. 1993). Within the study the authors utilized the NSM
and identified each participant as a unique individual and that approach was utilized
with individual treatment plans. The study also followed the NSM by categorizing
stressors into the three NSM of interpersonal, extrapersonal and intrapersonal
categories. The study developed a comparative design methodology to assess the
effectiveness of the program in reducing symptoms of anxiety disorders. The design of
the study identified 32 patients that fully met inclusion criteria, and their progress was
evaluated after a 5-week treatment plan. The study excluded patients who were active
with drug or alcohol abuse, psychosis, and potential danger to self, others, or property.
The researchers utilized tools of evaluation for each proposed hypothesis. For the "fear
of fear" category, the researchers used the Agoraphobic Cognitions Questionnaire
(ACQ) and the Body Sensations Questionnaire (BSQ). These tools were developed by

Chambless, Caputo, Bright, and Gallagher in 1984. To evaluate the severity of
impaired functioning question, the researchers used the Mobility Inventory for
Agoraphobia (MI) developed by Chambless, Caputo, Jasin, Gracely, and Williams
(1985). The MI tool was given to patients and asked the patients to complete a MI in
context of impairment when alone and an additional survey of impairment when
accompanied with others. The study considered the total number of attacks reported
and the two global numbers as well. To measure the question of psychological
symptom distress, the researchers utilized the Symptom Checklist 90-Revised (SCL90R) developed by Derogatis (1983). The demographics of the study showed 84% of the
participants were women, and the mean age of female participants was 35.9 years. The
male patients" mean age was 39.0 years, and the total mean age in the study was 36.4
years. Of the participants, 73.3% were married, 13.3% were never married, 10%
divorced, and 3% were widowed. Within the study, 84% of participants had a diagnosis
of panic disorder with agoraphobia. The other diagnoses consisted of agoraphobia
without panic attacks, obsessive compulsive disorder, and major depression. Another
finding showed that 16% of participants had a diagnosis of alcohol or benzodiazepine
addiction (Waddell & Demi, 1993).
The study excluded patients who were active with drug or alcohol abuse,
psychosis, and potential danger to self, others, or property. The researchers utilized
tools of evaluation for each proposed hypothesis. For the "fear of fear" category, the
researchers used the Agoraphobic Cognitions Questionnaire (ACQ) and the Body
Sensations Questionnaire (BSQ). To evaluate the severity of impaired functioning
question, the researchers used the Mobility Inventory for Agoraphobia (MI) developed

in 1985. The Ml tool was given to patients and asked the patients to complete a Ml in
context of impairment when alone and an additional survey of impairment when
accompanied with others. The study considered the total number of attacks reported
and the two global numbers as well. To measure the question of psychological
symptom distress, the researchers utilized the Symptom Checklist 90-Revised (SCL90R) developed in 1983. The demographics of the study showed 84% of the participants
were women, and the mean age of female participants was 35.9 years. The male
patients" mean age was 39.0 years, and the total mean age in the study was 36.4 years.
Of the participants 73.3% were married, 13.3% were never married, 10% divorced, and
3% were widowed. Within the study, 84% of participants had a diagnosis of panic
disorder with agoraphobia. The other diagnoses consisted of agoraphobia without panic
attacks, obsessive compulsive disorder, and major depression. Another finding showed
that 16% of participants had a diagnosis of alcohol or benzodiazepine addiction
(Waddell & Demi, 1993).
The data supported all of the hypotheses as described by the study in which each
category showed significant lower scores on the tools post-treatment than pretreatment.
Waddell and Demi (1993) stated that several of the propositions of the NSM were
validated with their findings. Data showed that, with strengthening of personal lines of
defense, the integrity of a person as a whole is protected. The study supported the NSM
proposition that levels of prevention can make great contributions to returning a client
to effective functioning. The secondary level of prevention strategies within the study
(treatment of symptoms) showed marked reduction of the Ml scores indicating
treatment success. The tertiary prevention level was served by efforts to find recovery

and the lower SCL90-R scores proved a good sign of recovery. Primary level
prevention was promoted with educational efforts in the treatment plan, but were not
measured, an identified need for additional study. Waddell and Demi (1993) identified
the following limitations to the study: (a) the lack of a control group, (b) the small
number ot actual patients who were fully measured in the study, (c) the lack of followup data on patients" progression after the 5-week treatment plan, and (d) the fact that
some of the participants were being simultaneously treated for benzodiazepine addiction
which has a withdrawal symptom of increased anxiety and agitation. An additional
limitation that may have been identified was the possibility of bias with the results from
patients" attempts to please the staff. The researchers identified several areas for future
research in this area and that a comparison or control group would help determine
effectiveness of treatments. Follow-up of patients post-interventions should also be
studied. The researchers also stated that future studies need to balance the gender of
participants and if there are differences with varying the types of medications in
treatment plans. The study indicated that IPHP treatment plans do decrease
agoraphobic symptoms, but the long-term effect of the treatment still remains an
unknown (Waddell & Demi, 1993).
In another NSM study, Inan and Ustun (2018) utilized the model to determine
the effects of home-based psychoeducational programs on distress, anxiety, depression,
and quality of life in breast care survivors. The study titled. Home-Based
Psychoeducational Intervention for Breast Care Survivors, identified breast cancer as
one of the most frequently diagnosed cancer in women. The study was based in the
country of Turkey where statistically breast cancer patients are younger and have more

advanced stages ot breast cancer as compared to developed countries. With advances in
treatment and early detection and diagnosis, the 5-year survival rate for breast cancer in
Turkey now sits at 77%. With the increase in breast cancer survival, breast cancer
survival-related issues also have increased. Many times, the treatment of cancer creates
problems, such as fatigue, physical dysfunction, body image distortion, pain, fear of
recurrence, and many other long-lasting issues. These and other issues many times lead
to anxiety and depression states. The study utilized the NSM as its framework in order
to identify reactions of clients to the stressors of breast cancer survival. The focus of
the study was identified as a tertiary prevention strategy of strengthening breast cancer
survivors with the use of psychoeducation. The study sought to investigate the
effectiveness of home-based psychoeducational programs on quality of life (QOL),
distress levels, anxiety, and depression levels of breast cancer survivors in Turkey. The
hypotheses of the study stated that breast cancer survivors will have reduced scores in
distress, anxiety, depression, and quality of life. Inan and Ustun (2018) utilized a onegroup pretest and posttest quasi-experimental design to determine the effectiveness of
intervention. The study utilized participants who were at least 3 months post-breast
cancer treatment. The demographics of the participants showed a mean age of 53.71
years. The majority of the participants were married (84.4%), and 84.4% were
unemployed. The participants of the study treatment regime showed that 78.1% had
breast preserving surgery, 93.7% had chemotherapy, 96.9% had radiation therapy, and
87.5% had hormonal therapy. Participants' treatment programs had a mean of 12.09
months to complete their therapy, and most survivors had stage II breast cancer (62.5%)
(Inan & Ustun, 2018).

The home-based education material was a booklet developed by the researchers
of a qualitative study who were experts in psycho-oncology, breast cancer, and the
NSM. The booklet was reviewed by a registered nurse who had 15 years of experience
working with breast cancer patients and two expert clinicians who had experience with
clinical and academic experience with psycho-oncology and breast cancer. The
interventions were home-based sessions that lasted one to one-and-a-half hours in
length and were held at one-to-two-week intervals depending on whether or not major
problems were found. There were four total sessions with each participant, and
researchers evaluated and discussed each participant weekly. Data were collected
during a 16-month time period, and participants completed the pretest after consent was
established. The study utilized the Distress thermometer (DT). a scale used to identify
common problems experienced by cancer patients to measure psychological distress.
The study also utilized the Hospital Anxiety and Depression Scale (HADS-D) for
depression measurement and the HADS-A for anxiety measurement. To establish
quality-of-life measurement, the study utilized the Turkish version of the World Health
Organization Quality of Life Instrument (short form). Inan and Ustun (2018) indicated
that the intervention home-based psychoeducational program was effective in reducing
levels of anxiety, distress, and depression. The researchers also stated that the
intervention increased perceived QOL in the participants of the program, but no more
than interventions in previous studies. The major problem identified by the participants
was fear of recurrence. This problem was consistent with the literature reviewed and
points to the only slight increase in QOL perception of the participants.

The researchers identified the limitation that this study was not a randomized
control study and that improvements noted in this study cannot be based upon the
interventions alone. The researchers also identified the fact that the study had a small
sample size in Turkey, and results may not be generalizable to other countries. The
study concluded that nurses have a critical role to play in survivorship care and
development. The study asserted that many times in Turkey survivors of breast cancer
post-treatment care is physician-led, and the treatment plan many times lacks
psychosocial support. The researchers stated that Turkish oncology nurses should
assess survivors for distress domains and advocate for psychoeducational interventions
so patients may cope with these symptoms. The researchers also stated that nurses
should encourage spouses and family members to support survivors in their
posttreatment period (Inan & Ustun 2018).
The NSM's focus on how stressors precipitated reactions in the client system
was a central key to the studies reviewed above. Both studies looked at the client as an
open system that is constantly looking for homeostasis and will adapt either negatively
or positively to the stressors around the client system. The model requires nurses to
perform primary, secondary, and tertiary prevention interventions that strengthen the
client's ability to respond to stressors and obtain system stability (Inan & Ustun, 2018).
In addition, the NSM states that stressors must be classified in order for nurses to
support clients in their return to stability. In the model stressors that are interpersonal,
intrapersonal, and extrapersonal must be identified, and the nurses should play an
important role in helping the client find and adapt to these stressors (Waddell & Demi.
1993).

The NSM was used as a framework for the current study. The current research
was conducted to ascertain plan of treatment for general anxiety by healthcare providers
in Mississippi. Even though no general clinical practice guidelines existed, the
researchers determined by data compilation the plan of treatment that five primary care
clinics in Mississippi had used to treat GAD. With possible new restrictions for certain
pharmacological treatments looming, the researchers were interested in what treatments
providers are utilizing and what methodology they use to prescribe treatment.
The research group chose the NSM based on its broad nature, adaptability, and
the model's representation of the client as an open system that is in constant interaction
with the environment. With new restrictions for the use of some of the treatment plans
that may be introduced in the near future, many patients will be faced with new
stressors in their general anxiety treatment plan. With utilization of the NSM and its
open system, the current researchers are committed to identifying possible new stressors
that could be added to the treatment of GAD with the new changes. With the NSM, the
patient is to be assessed in a holistic manner that includes all aspects of the patient and
their environment. By utilizing the wholistic approach, this research focused on
defining what the current treatment ideology is for GAD in northern Mississippi. The
questions the study may answer will provide the researchers and perhaps others with
data that may help bring about change in the treatment plans and provide patients with
firm adaptation answers that will reduce these patients' stressors and return them to
stability in management of their general anxiety.

Review of Related Research
Ruscio et al. developed a study to close the knowledge gap about the incidence
and seriousness of GAD in the world. Although GAD is a recognized mental disorder,
little to no epidemiological data about the condition exist. Ruscio et al. surveyed adults
in 26 countries over a period of 11 years to supplement information regarding the
disorder in the fifth edition of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-5). The results of the study provided information about the prevalence
of GAD worldwide, as well as information about the gravity of the condition as a
debilitating mental health disorder with implications for role impairment and comorbid
conditions.
The research objective of Ruscio et al. (2017) was to provide global
epidemiological data about GAD, including its incidence, impact, and health correlates.
Ruscio et al. listed an analysis of competing hypotheses. First, they speculated that
although existing data suggested GAD was prevalent in industrialized countries, it
would also be prevalent in developing nations where poverty, political instability, and
fear for the future are rampant. Second, Ruscio et al. hypothesized that GAD could be
less prevalent in developing countries where anxiety is typically characterized by
somatic rather than cognitive symptoms. The researchers did not credit a theoretical
framework with guiding their research.
The study by Ruscio et al. (2017) was conducted among 147,261 adults from 18
to 99 years old in 26 countries over 11 years from 2001-2012. Although the authors do
not elaborate on details of the sampling process, they stated that a nationally or
regionally representative sample of the average household population was achieved.

The sample was eategorized by income level relative to each country: low to lowermiddle, upper-middle, and high income. The study was then conducted using a crosssectional general population survey with a two-phased interview process. In the first
phase, the subject was assessed for a core set of mental disorders, including GAD.
Subjects identified as having a mental disorder were assessed with the second interview
phase, which analyzed for comorbidities and additional mental disorders. The interview
tool used was the World Health Organization Composite International Diagnostic
Interview (C1DI), a validated, structured interview tool administered by laypeople to
determine epidemiological data about GAD (Ruscio et al., 2017).
The first phase of CIDI formed the basis for the epidemiological data regarding
GAD worldwide. Results were further refined by length of GAD symptoms: 30 days,
12 months, or lifetime. Subjects identified as having 12-month or lifetime GAD were
further assessed for role impairment with the Sheehan Disability Scale. The second
phase of CIDI provided data related to comorbidities of GAD, including other anxiety
disorders, mood disorders, behavioral disorders, and substance-abuse disorders.
Sociodemographic variables were also obtained, including age, sex, employment status,
income, marital status, and educational background. Subjects were interviewed about
seeking treatment in the previous 12 months, whether from primary care, psychiatric
care, human services, or alternative medicine practices.
Ruscio et al. (2017) performed statistical analysis with cross-tabulations to
discover prevalence, comorbidity, impairment, and treatment for GAD. Logistic
regression, actuarial analysis, and further statistical analyses were performed to
detennine age-of-onset data and sociodemographic correlation. Statistical significance

was determined through Wald and McNemar chi-square tests. A standard statistical
significance ofp < .05 was used.
Statistical analysis from the study revealed a plethora of information about
GAD, its prevalence, and sociodemographic correlates. The worldwide prevalence of
GAD was found to be 3.7% for lifetime, 1.8% for 12 months, and 0.8% for 30 days.
Lifetime prevalence of GAD was discovered to be higher in upper-income countries,
with Australia and the United States having the greatest prevalence at approximately
8%. Sociodemographic correlates for GAD included female sex, age < 60 years, and
unmarried status. Lower educational level, lower income, and underemployment were
strongly correlated with GAD. The typical age-of-onset for the disorder was
cumulative throughout the lifespan: 25% of cases emerged by age 25 years, 50% by age
39 years, and 75% by age 53 years. Earlier age-of-onset was correlated to persistence
of the disorder. Although overall incidence of GAD was higher in upper-income
countries, lifetime cases of GAD were more persistent in low-income countries.
Results from this study yielded information regarding comorbidity, role
impairment, and treatment-seeking of GAD. In total, 81.9% of subjects with lifetime
GAD and 70.8% of subjects with 12-month GAD were found to have a comorbid
psychiatric condition. Major depressive disorder was the most common comorbid
condition with GAD discovered to be present in 52.6% of GAD lifetime cases and in
40.9% of 12-month GAD cases. Half of patients with 12-month GAD reported severe
disability in one or more life domains, with an average reporting of being unable to
work or carry out daily activities on 40 days in the preceding 12 months. Complaints of
role impairment related to GAD were highest in high-income countries, including the

United States. Regarding treatment-seeking, only approximately half of subjects with
12-month GAD received some form of mental health treatment in the previous year.
Subjects with comorbid conditions were more likely to seek treatment than patients with
GAD alone. Treatment rate for GAD was higher in upper-income countries, but there
was a global trend of more patients seeking treatment for GAD symptoms (Ruscio et ah,
2017).
The findings of the study justified the objective for the research. Global
prevalence of lifetime GAD cases was 37-90% greater under the DSM-5 criteria than it
had been under the DSM-4 criteria. The higher comorbidity of GAD with major
depressive disorder is also notable for primary and psychiatric care providers. The
researchers stressed that patients with GAD require systematic assessment and
appropriate management. The authors' second hypothesis that prevalence of GAD
would be higher in more economically prosperous nations proved correct. However,
Ruscio et al. (2017) wrote that further research in developing nations was warranted to
exclude the possibility of underreporting of symptoms or overlooking non-cognitive
symptoms of anxiety.
One of the greatest strengths from this study was the large and diverse sample.
The large sample size allowed for rigorous statistical analysis, which in turn permitted
broad application to primary care practice. Another asset to this study was the clear,
succinct writing style with easily summarized findings.

Overall, the findings from this

study by Ruscio et al. (2017) filled a large knowledge gap about a significant medical
problem.

However, there are some weaknesses in the study as well. It is unclear why the
Riscio et al. (2017) decided not to elaborate on the sampling procedure. More
information about the sampling process would boost trustworthiness in the
methodology. Also, the authors stated that the face-to-face interviews with subjects
were administered by laypeople with consistent training and field quality control
procedures. The reader would be more confident in these assertions if they were
explained in detail. The authors themselves stated limitations in the study related to
statistical analysis, namely that the measure of persistence could not distinguish
between chronic and recurrent or resolved cases of GAD and that prevalence estimates
using the CID1 tool tend to be conservative. Ruscio et al. (2017) also acknowledged the
possibility of methodologic variation due to large differences in prevalence from
country to country.
There were multiple implications from this study for the current research. First,
Ruscio et al. (2017) revealed the widespread prevalence of GAD in the American
population as well as the myriad significant accompanying symptoms. Even simply the
economic implication of missed days of work due to GAD is noteworthy. Second, the
findings of Ruscio et al. reinforced the importance of recognizing and treating GAD in
the patient population. Given the study's findings, namely the high prevalence of GAD
among Americans and the fact that only half of patients with 12-month GAD
spontaneously seek treatment, primary care providers will need to be prepared to adjust
their practice. By incorporating the findings of this study by Ruscio et al. (2017) with
evidence-based practice regarding treatment of GAD, American healthcare providers

will be able to improve quality of life for a significant portion of the population
suffering from the disorder.
Remes, Brayne, van der Linde, and Lafortune (2016) perfonned a systematic
review of current studies regarding prevalence of anxiety disorder in adult populations
using Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement
(PRISMA). Within this systematic review, the authors were seeking definitive answers
that would produce a wide and descriptive view of the prevalence of anxiety disorders
in the general adult population as well as inpatient and outpatient groups burdened by
physical disability and psychiatric disorders. Within the United States alone, anxiety
disorders are estimated to be as high as 18% of the general population and at an annual
cost of more than S42 billion (Greenberg et ah. 1999). In the European Union (EU),
there were estimates of 60 million people affected by anxiety disorders each year
making this condition the most prevalent psychiatric condition in the EU (Wittchen et
ah, 2011). With the stated results of what anxiety disorders cost as far as quality of daily
lives lived and the monetary costs derived from these disorders, this review proposed to
provide a quality comprehensive look at the fragmented areas of previous studies and
combine their data to promote other studies and provide a template for review of the
burden of anxiety in the world.
Remes et ah (2016) proposed that the data reviewed in their study would answer
questions as to what groups are most affected by anxiety disorders. The researchers
hoped that results would define areas of anxiety disorders that need additional research
and prompt more studies on the condition.

1 his systematic review was derived from a PRISMA and Cochran collaboration
model of reviews to meet the quality of the data mission statement. The search yielded
48 systematic reviews that met inclusion criteria. The inclusion formula looked for
reviews that reported prevalence of generalized anxiety disorder (GAD), obsessivecompulsive disorder (OCD), social anxiety disorder (SAD), panic disorder (PD), and
anxiety not otherwise specified (NOS). In this formula, reviews were utilized
regardless of sampling framework and regardless of tool type for assessment of anxiety
disorders. Techniques such as interviews administered by clinicians or trained
professionals, symptom checklists, and clinician diagnosis were all included in the
formula. Interviews and self-reported questionnaires that were included must have
utilized standard systems of classification from the Diagnostic and Statistical Manual of
Mental Health Disorders (DSM) (American Psychiatric Association, 2010) or the
International Classification of Diseases (ICD) (World Health Organization, 2016)
exclusively. In assuring a quality review, all articles meeting inclusion guidelines must
have met at least five of the criteria established by AMSTAR, a quality assessment that
defines whether an article utilized a prior knowledge design and whether a duplicate
study and or data extraction were utilized. In addition, this standard required a
comprehensive literature search as part of the parameters and quality of the primary
studies. In the review, data extraction and analysis were centered on five common
themes and prevalence was established in the context of:
(1) addiction, (2) other mental and neurological disorders, (3) chronic physical
diseases, (4) trauma, and (5) vulnerable population sub-groups and if a study on
chronic physical disease had fewer than three reviews it was grouped as other

chronic physical disease or placed with other chronic physical diseases in end
state. (Remes et ah, 2016, p. 3).
Within some ot the reviews, prevalence of anxiety disorder was classified as
male or female, and these data were included, but the standardized inclusion method did
not include having data quantified by sex. This information was thought to be relevant
and opens the door for future research as well.
Upon inspection, the reviewers utilized 48 total reviews to help identify the
prevalence of anxiety disorders in population sub-groups and environments as listed by
these combined reviews. Even though there was a large amount of differences in the
prevalence reporting of these reviews, there was compelling evidence that shows a large
prevalence of anxiety disorders around 3.8 to up to 25% among the general population.
Prevalence numbers, as defined by sex, age, and chronic disease in the review, also
identified some of the sub-groups which brought about future research needs as all
reviews did not identify sub-groups. The prevalence numbers identified within the sub
groups were as follows: 5.2 - 8.7% for women, 2.5 - 9.1% for young adults, and 1.4 70% for those with chronic disease processes. These sub-groups, combined with the
general population data, show that prevalence numbers have a wide range of
differences, especially in the sub-group populations. These discrepancies, even in a
highly systematic review, showed the need for routine screening methodology when
searching for prevalence numbers in anxiety disorders. Within this review, many
recommendations for future studies were unearthed. Recommendations included
utilization of longitudinal design studies to define acute states versus chronic states of
anxiety disorders. Studies of diagnostic standardizations with respect to measurement

ot psychiatric disorders were also found as well as studies that incorporated
standardized tools for screening for the possibility of anxiety disorders. The lack of
quality studies on treatment or interventions to alleviate anxiety were also identified.
Finally, the review showed a need for further research on anxiety levels pre-treatment
and post-treatment to prompt a thorough assessment of what treatments are relieving
anxiety (Remes et ah, (2016).
This systematic review has shown that there is a high prevalence of anxiety
across the globe and anxiety disorders are increasingly recognized as a determinant to
poor health and major consumer of health services dollars. The review also revealed
many different avenues of critical research that needs to be continued in order to plan a
prompt and quality attack on anxiety disorders and research on treatment modalities that
best suit each disorder in the anxiety disorder heading. The limitations of having a high
degree of different methods of anxiety assessments played a big part in the differences
in prevalence estimates as reported. This unfortunate variable limited the study's ability
to draw specific conclusions that would show the specific burden anxiety disorders
placed on individual patients and groups within the globe.
The reviewers identified limitations to the review. The reviewers found that
even though large databases were used in identifying reviews, it is possible that some
reviews were not found and missed. In addition, another limitation identified was the
large degree of difference in the anxiety assessment tools and the sampling methods of
the primary studies which made it hard to accurately draw conclusions in regard to the
burden of anxiety disorder. Another limitation was a large number of the reviews were
studies that were taking place in the western setting which made it challenging to

compare the results with other parts of the world. The greatest strengths of the review
were the amount of diversity the review considered. By being inclusive of sub-groups
and utilizing worldwide studies, the results showed that anxiety disorder is not only a
United States problem but a world-wide problem. The focus placed by being inclusive
of all parts ot the world and multiple cultures and races help bring awareness to the
burden anxiety disorder is to all people across the globe.
This article review puts into context the prevalence of general anxiety in adult
populations. Within the review, data were identified that showed women are almost 2
times more likely to suffer with anxiety disorder than men (Baxter et al., 2013; Somers
et ah, 2006; Steel et ah, 2014). In addition, the review revealed that individuals under
the age of 35 years are more likely to be affected by anxiety disorders (Baxter et ah
2013, 2014). The results from this review, although limited in some context, will
provide some much-needed statistical data that has been stratified through a quality
systematic review model to eliminate as much bias as possible and provide quality data.
Although the current study concentrated in the northern Mississippi area, the study is in
one of the categories identified as areas of future research. Northern Mississippi is an
area of unique culture and diverse population in which the review identified as an area
for future research in the prevalence of anxiety disorder. The current research studysought to evaluate healthcare providers treatment of anxiety disorders and data gathered
from this review was invaluable in helping the current research team determine patient
groups to include in the study.
Roberge et al. (2015) performed a qualitative study for the purpose of
determining usage of mental health services, exploration of recommendations from

clinical practice guidelines being followed involving GAD. and examining treatment
adequacy. GAD is a significant problem in primary care settings presented with
persistent anxiety and worry that can debilitate a patient psychologically, physically,
emotionally, and even financially. GAD is very challenging to detect, especially in
primary care settings and this has been credited to the vague symptoms associated with
GAD. Symptoms often are perceived as somatic physical symptoms and do not
necessarily point to GAD. Patients often have comorbid conditions that overlap, thus
creating a challenge for primary care providers. Data sources used for this research
project included the "Dialogue" project, a large primary care study conducted in 67
primary care clinics in Quebec, Canada (Roberge et al, 2015, p. 1). Data were obtained
using the waiting room questionnaire survey. The researchers utilized the Anderson's
Behavior Model of Health Care as the framework for the evaluation of the individual
and contextual characteristics correlated with service use. This framework helped the
researchers view treatment adequacy while taking into consideration predisposing,
enabling, and need for care factors.
Roberge et al. (2015) identified the hypothesis, "GAD recognition and the
presence of comorbid depression would improve the likelihood of treatment adequacy
for primary care patients" (Roberge et al, 2015, p. 2). The researchers sought to achieve
increased awareness of the inadequacy of the recognition and. therefore, treatment of
GAD in primary care. Since it is preferred to diagnose and treat GAD in primary care,
adequate recognition and adequate treatments are necessary.
A large cohort study, the "Dialogue," supplied portions of data for this research,
and the remainder of data were retrieved from a questionnaire survey. The

questionnaire was placed in 67 waiting rooms of primary care clinics at random times
during the data collection period. A total of 22,600 eligible patients were approached to
determine it they met initial criteria. Individuals needed to be at least 18 years old, able
to read the questionnaire in English or French, and at the clinic to consult a provider for
themselves. Out of the 22,600 approached. 67.4% completed the screening
questionnaire. The screening questionnaire gathered information about medication,
demographics, heath status, and consultations with providers.
After the initial communication at the clinics, the participants were asked to
participate in a survey if they met certain criteria. Criteria included "elevated anxiety or
depressive symptoms, anxiety or depression medication in the past 12 months,
diagnosis of anxiety or depression, or consultation for mental health illness in the past
12 months" (Roberge. et. al.. 2015. p. 3). The survey was divided into two portions.
The first portion included a psychiatric evaluation that focused on the DSM IV criteria
for common mental illness disorder's diagnostic criteria. If the participant did not meet
criteria for diagnosis, then they were not allowed to continue. The second portion
included 1.956 out of 4,506 individuals who agreed to participate. These participants
needed to have any of the following to meet criteria to continue: diagnostic criteria of
GAD, social phobia, panic disorder, agoraphobia or depression via DSM IV in the last
12 months, high anxiety and depression levels despite medication use, healthcare
professional diagnosis, and diagnostic criteria of depression or anxiety in the past 24
months. The second portion of the survey included questions regarding experience of
the care received, resources utilized, medication usage, and perceived needs for care.
The final sample used for the present study included 373 adults that met the criteria for

GAD. Roberge et al. (2015) further investigated indieations and detection of GAD,
service utilization and treatment adequacy by utilizing the information from the survey.
These researchers discussed adequate pharmacological treatments as using a first-,
second-, or third-line agent and to have a minimum of three visits with the provider.
The researchers noted that benzodiazepines are not labeled as adequate treatment for
GAD as they are only recommended for short-term adjunct medications. The
researchers defined adequate psychotherapy by a provider at a clinic as having a
minimum of 12 sessions with the same provider and a cognitive behavior treatment.
Adequacy of treatment was met if the patient received one or both treatments.
The information gathered was used to determine if patients with GAD and
comorbid depression would improve adequacy of treatment. The variables of interest
for the study was the influence of comorbid depression on adequacy of treatment and
recognition of GAD in primary care.
Following analysis, Roberge et al. (2015) determined that the hypothesis was
supported with evidence: "71% of participants also met criteria for major depression,
and 60.6% had a comorbid anxiety disorder" (p. 4). The results also showed that 82.6%
of participants had a chronic physical condition. The survey showed the most common
healthcare professionals consulted for GAD treatment were primary care providers.
The results also showed that individuals who were divorced, widowed, or separated
were more likely to obtain pharmacological treatment than single individuals.
Psychotherapy adequacy of treatment showed a low percentage in that only 19.2% of
reported psychotherapy actually qualified as an adequate treatment. The researchers
stated that a high number of patients were taking benzodiazepines long-term despite

clear guidance from the Canadian Psychiatry Association stating they should not be
used tor long-term treatment. Researchers also stated that "improving recognition of
GAD in primary care could lead to an increase in guideline-concordant care" (Roberge
et al, 2015, p. 8).
Several weaknesses were identified by the researchers in the study. Research
relied on sell-reporting data and differences between self-reporting data and
administrative data have revealed significant differences in previous studies. Results
also only offered a partial view of treatment adequacy and did not take into
consideration that service utilization therapy could have affected needs for care.
Indicators of treatment adequacy did not acknowledge characteristics, such as patient
preference and other factors associated with care quality. Roberge et al. (2015)
recommended further research be conducted on GAD screening and diagnosis.
This study by Roberge et al. (2015) was relevant to the current study as it
provided evidence of the challenges faced with management of GAD. In the literature,
Roberge et al. noted that benzodiazepines were not to be used as long-tenn treatment,
yet they still observed significant usage in long-term treatments. GAD management
remains a challenge: but, with better recognition and utilization of evidence-based
treatments, outcomes can be optimized for patients with GAD.
Weisberg, Beard, Moitra, Dyck, and Keller (2014) developed a study to evaluate
whether or not patients with anxiety disorders were receiving adequate care for their
anxiety from primary care providers. The study was developed due to a perceived need
for increased attention to anxiety disorders. Anxiety disorders make up the most
frequently diagnosed mental health condition and are highly correlated to role

impairment, decreased quality of life, and suicide. Moreover, anxiety disorders are
increasingly diagnosed and managed in the primary care setting rather than psychiatric
setting. While pharmacologic treatment of anxiety disorders in the primary care setting
has become somewhat standardized, many areas of the United States have inadequate
access to psychotherapy clinics where patients may have access to cognitive-behavioral
therapy (CBT), an efficacious, first-line treatment for anxiety.
The research objective of the study by Weisberg et al. (2014) was to close a
knowledge gap about adequacy of mental health services for patients who present with
anxiety in the primary care setting. Weisberg et al. (2014) stated that there was scarce
literature regarding this topic, and none that specifically addressed the region in which
the study was conducted—northeastern United States. No specific hypotheses were
given, and Weisberg et al. (2014) did not credit a theory with guiding their research.
Research conducted by Weisburg et al. (2014) was an observational,
longitudinal study among 539 patients of 15 primary care practices in Vennont. Rhode
Island, Massachusetts, and New Hampshire from 1997-2001. Inclusion criteria for the
study included the following: a general medical appointment that same day, proficiency
in English, aged 18 years or above, and a diagnosis of an anxiety disorder according to
the fourth edition of the Diagnostic and statistical manual of mental disorders (DSM-4).
This included panic disorder with or without agoraphobia, social anxiety, generalized
anxiety disorder (GAD), posttraumatic stress disorder (PTSD), agoraphobia without
panic disorder, mixed anxiety-depressive disorder, or GAD symptoms exclusively
during a mood disorder. Criteria for exclusion were pregnancy, active psychosis, or no
current address or phone number. Eligible participants were told they were being

recruited for a study on stress or nervousness and were screened for anxiety using a
validated anxiety screener.
Following confirmation from the screening tool, subjects were given a
diagnostic interview using the Structured Clinical Interview for DSM-4 (SCID).
Subjects were interviewed at the initiation of the study, at 6 months, 12 months, and
then annually for up to 5 years. Most participants were female and Caucasian with an
average age of 39-years-old. Panic disorder and PTSD were the most common primary
anxiety disorders.
Participants were questioned about four domains related to anxiety. First,
psychosocial functioning was evaluated through the Global Social Adjustment (GSA)
tool from the Longitudinal Interval Follow-up Evaluation for DSM-4 (LIFE). Nonpsychiatric medical problems were assessed through an original medical history form.
The second domain measured was treatment. Subjects were questioned about any
treatment for anxiety in the preceding 3 months at the beginning of the study, and then
throughout the study the participants were questioned about treatment since the
previous interview. Pharmacological treatments were recorded in the psychotropic
intake form of the LIFE tool, while psychotherapy treatment was recorded using the
Psychosocial Treatment Interview-Revised (PTI-R). Weisberg et al. also recorded
whether the prescribing clinician was a primary care provider or psychiatrist. The third
domain of measurement was potentially adequate pharmacotherapy. Definitions for
adequate pharmacotherapy were borrowed from the findings of a previous study.
Participants were considered to be receiving adequate pharmacological treatment if they
were taking a selective serotonin reuptake inhibitor (SSRI), serotonin norepinephrine

reuptake inhibitor (SNRI), benzodiazepine, buspirone, gabapentin, or pregabalin. The
same study s findings were used to determine il the dosages of the drugs were
appropriate. Adequate duration of pharmacological treatment was considered to be 8
weeks duration at a minimum. The fourth and final domain studied in the research was
potentially adequate psychotherapy. Weisberg et al. considered potentially adequate
therapy to be cognitive therapy (CT), behavioral therapy (BT), or combined cognitivebehavioral therapy (CBT).
Weisberg et al. (2014) used descriptive statistics to summarize the results of the
study. Statistical methods included chi-square analysis of treatment adequacy. Six
dependent variables were created to evaluate predictors of potentially adequate
pharmacotherapy: (a) adequate medication therapy at intake, (b) adequate
psychotherapy treatment at intake, (c) any adequate treatment (medication or
psychotherapy) at intake, (d) adequate phannacologic treatment at follow-up, (e)
adequate psychotherapy treatment at follow-up. and (f) any adequate treatment modality
(medication or psychotherapy) at follow-up. Predictors for each outcome were
examined, including age, sex, race, college education (yes or no), insurance type,
income (whether less than or greater than $20,000 per year), marital status, and function
level according to GSA. Comorbidities of other illnesses were examined, including:
major depressive disorder, substance-use disorder, other anxiety disorders, and nonpsychiatric medical illness. Age of onset of the anxiety disorder was also evaluated.
Logistic regression examined all of these dependent variables with a standard
significance level of 0.05.

At the end ot the study, 419 participants were qualified to be analyzed for
treatment adequacy at follow-up. The remaining 120 participants, who had dropped out
of the study, were analyzed for potential factors affecting dropout. These subjects were
typically younger but did not have any other statistically significant demographic
characteristics, baseline GAF score, or inadequate treatment for anxiety (Weisberg et
al., 2014).
Regarding adequacy of treatment received at intake. 37.45% of participants
reported receipt of an appropriate anti-anxiety medication. Of these, 26.4% were taking
a SSRI or SNRI. 17.42% were taking a benzodiazepine, and 0.19% were taking
buspirone. No subjects were taking gabapentin or pregabalin. Only 19.1% of subjects
had been on an adequate medication treatment for the appropriate duration of 8 weeks.
Data were analyzed on 193 participants to discover which kind of provider had
prescribed the pharmacotherapy treatment and was revealed to be divided evenly
between primary care and psychiatric clinicians. Related to psychotherapy, only a third
of subjects had received any kind of psychotherapy in the preceding 3 months before
intake. Of these, 12.76% had received CT, 5.26% had received BT, and 14.42% had
received another mode of psychotherapy. Overall, 28.28% subjects had received any
kind of adequate anxiety treatment, whether from medication, psychotherapy, or a
combination (Weisberg et al., 2014).
Predictors for receipt of adequate treatment at intake were evaluated using
logistic regression. Individuals with panic disorder or insurance were more likely to
have received adequate medication therapy. Improved scores on GSA. unmarried
status, and college education were predictors of adequate psychotherapy at intake.

Racial minoiities were less likely to have received adequate psychotherapy. Predictors
ot adequate treatment of any modality were diagnosis of panic disorder, college
education, worse scores on functioning, and income < $20,000. Participants with
married status, no insurance, and ethnic minority membership were less likely to have
received adequate care.
At 3 months follow-up from intake, 70.41% of participants reported taking an
appropriate pharmacological agent. Of these, 62.05% were taking an SSR1 or SNRI,
and 34.37% had taken a benzodiazepine. Among subjects diagnosed with GAD, 5.34%
were taking buspirone, and 0.89% were taking gabapentin. Overall, 60.38% of subjects
were taking adequate anti-anxiety medication for the minimum 8 weeks. Regarding
adequate psychotherapy. 60.38% of participants had received some fomi of therapy in
the 3 months since intake. Of these, 33.89% received CT, and 21.48% received BT.
Altogether, 36.27% of subjects had received potentially adequate psychotherapy of any
kind during the time since intake. Considering psychotherapy and pharmacological
therapy together, 69.21% of the participants had received any modality of potentially
adequate treatment at the 3-month follow-up period.
Predictors for patients receiving adequate phannacological therapy at follow-up
included a diagnosis of panic disorder, social disorder, or major depressive disorder at
intake and income < $20,000. Patients of ethnic minorities were less likely to have
potentially adequate pharmacotherapy. Predictors for adequate psychotherapy included
college education, worse scores of functioning on the GSA, income < $20,000, and
diagnosis of PTSD at intake. Ethnic minorities were less likely to have received
adequate medication treatment for anxiety. Predictors for adequate anxiety treatment of

any modality at follow-up included having a diagnosis of major depressive disorder,
panic disorder, and coverage under Medicaid or Medicare insurance. Once again,
participants who were in ethnic minorities were less likely to have received potentially
adequate care of any kind at follow-up.
Altogether, participants in the study were found to be undertreated for anxiety at
intake. However, over the years of follow-up, studied from 2002-2007, patients began
to be more adequately treated. Adequate pharmacological treatment increased from
19.1 % at intake to 60% at the end of the 5 years. Potentially adequate psychotherapy
increased from 14.42% to 36% in the same timeframe. The total adequacy of treatment
of any modality increased from 28.28% to 69%. Weisberg et al. (2014) proposed a few
rationales to explain the increase in treatment. First, patients with subacute anxiety
might have begun to have more severe manifestations over time which prompted
clinicians to seek active treatment. Second, many primary care providers are likely to
refer patients to CBT only after other treatments are considered unsuccessful. Third,
the increase in treatment might reflect a broader effort in healthcare to address anxiety,
including influence from direct-to-consumer marketing of medications and guidelines
from the Food and Drug Administration (FDA). Moreover, the researchers admitted
that the increasing time intervals of follow-up may have falsely portrayed an increase in
treatment over time. It may be the case that when longer time intervals are studied, the
likelihood is higher that the patient has eventually received adequate care.
Participants with panic disorder were among the most likely to receive adequate
pharmacotherapy. This was attributed to the fact that the FDA has standardized
guidelines for medication treatment of this disorder. Higher educational level was

associated with adequate psychotherapy, which the authors attributed to possible bias on
behalf of the providers for which kind of participants were likely to benefit from CBT.
The authors suggested that increased attention be given to adapting CBT for patients of
lower educational levels. Significantly, ethnic minorities were less likely to receive
adequate care overall but this was not associated with low income levels. The authors
suggested that perhaps cultural beliefs regarding mental health treatment was the
explanation for this disparity.
The authors identified multiple limitations in the research. First, the study was
localized to a specific geographic location, the northeastern region of the United States.
Interestingly, CBT is more abundant in this location and thus the level of psychotherapy
treatment adequacy might be higher in this region than it would be elsewhere in the
United States. Second, the measure of psychotherapy from the research did not include
newer modalities of treatment such as mindfulness meditation and acceptance. The
number of psychotherapy sessions and the length of those sessions were also not
covered in this research. Third, the researchers stated that their inclusion of
benzodiazepines as a potentially adequate pharmacotherapy could have altered the
results. Given that benzodiazepines are controversial as a treatment for anxiety
disorders, the inclusion of this class of drugs might have falsely raised the levels of
adequate pharmacological treatment for participants. Fourth, the use of retrospective
self-report might not be an accurate method of data interpretation. Considering that
two-thirds of the primary care patients at the beginning of the study declined to be
screened for the study and that 40% of subjects who screened positive for anxiety
disorders did not follow-up for the SCID. there is a possibility that the subjects who

completed the study were receiving higher quality treatment and thus skewed the
results. A fifth limitation identified from the study is that there was a concerted effort
to support integrated care at the primary care level during the follow-up time period
(2002-2007), which might have altered the results of adequate treatment for anxiety
disorders.
In addition to the limitations identified by Weisberg et al. (2014), there are a few
other weaknesses in this study. While the statistical analysis of data were strong, the
authors summarization of the findings was obtuse at times. Information about the
sample and methodology were scattered throughout the article, which confuses the
reader. For example, the dates of the intake and the dates for the follow-up should have
been in one statement. Additional tables and figures illustrating the statistical findings
would facilitate more ease in reviewing the data.
However, there are many strong elements to the study. The research objective
was fulfilled by closing an established knowledge gap regarding adequacy of treatment
of anxiety disorders in the primary care setting. The authors' anticipated finding that
treatment was inadequate was confirmed. The length of the study was an asset to the
research as it allowed for a wealth of information to be accumulated. Notably, despite
the long-term nature of the study, the sample size of the study remained sufficiently
large for good data analysis to be completed. Performance of dropout analysis gives the
reader confidence in the integrity of the study and confirms that the lack of completion
did not skew the final results. The tools used to collect the data, including the anxiety
screener. SCID. GSA, and FIFE interview, were validated and reliable instruments.

Finally, in spite of the sensitive nature of research involving anxiety, the methodology
of the study seems to have avoided causing harm or distress to the participants.
The findings ot this study by Weisberg et al. (2014) were relevant to the current
research. First, the study continued that the management of anxiety disorders is
relevant tor primary care practice. Primary care clinicians must be well-versed in
recognizing and treating these disorders in order to prevent bad outcomes for their
patients. Second, the study illustrated how treatment of anxiety disorders should be
approached with consideration of multiple modalities. While the decision to pursue one
modality over another might be left to the discretion of the provider and the patient,
careful consideration should be given to both pharmacotherapy and psychotherapy.
However, the study highlighted the inadequacy of CBT treatment for patients with
anxiety disorders. In fact, Weisberg et al. (2014) admitted the abnormal availability of
CBT in the northeastern United States. It is likely that access to CBT is scarcer in other
regions, including northern Mississippi. Increased resources must be allocated to
providing CBT for primary care patients across the United States in order to treat
anxiety disorders effectively. Third and finally,

it is notable that Weisberg et al. (2014)

credited academic studies with defining adequate psychotherapy and pharmacotherapy.
While there was no reason to doubt the credibility of these studies, it is noteworthy that
there was no established clinical guideline from an authoritative body to determine what
constituted adequate treatment for anxiety disorders. With the development of a
standardized set of clinical practice guidelines from an authoritative body, it is possible
that more patients suffering from anxiety would receive adequate treatment.

Muntingh et al. (2014) performed a cluster randomized control trial for the
purpose of determining the effectiveness of collaborative stepped care (CSC) to care as
usual (CAU) treatment ot general anxiety disorder (GAD) by primary care providers in
the Netherlands. In the primary care setting, Muntingh et al. identified GAD and panic
disorder (PD) as two of the costliest and disabling diagnoses within anxiety disorders.
GAD and PD were identified as chronic conditions in which many times patients
diagnosed with these disorders continue to suffer 5 years post-treatment. The research
stated that most patients who suffer from GAD and/or PD will seek care from their
primary care provider, and many times these providers may be ill equipped to provide
psychotherapy, pharmacotherapy, and means of monitoring effectiveness of the therapy
and the prevention of possible relapse. In a response to the possible shortcoming of
primary care treatment for GAD and PD, the study revealed the development of
collaborative care models that provide general practitioners (GP) a model that delivers
evidence-based care that is continuous in nature. The participants of the study were
selected by meeting the inclusion criteria by answering the following parameters;
patients had to be at least 18 years old with an existing diagnosis of panic disorder with
or without agoraphobia and/or generalized anxiety disorder. Exclusion criteria was as
follows: patients with suicidal idealizations, dementia, or other severe cognitive
disorders, inability to understand the Dutch language, drug or alcohol dependency,
psychotic disorders, bipolar disorder, those with unstable medical conditions, or those
receiving psychological treatment that included at least 2 or more visits per month. In
addition, the study allowed patients who were already receiving antidepressant
medications prior to and during the study to continue their prescription.

Within the review ot literature, the group identified studies that concluded
collaborative care is a better treatment plan for GAD and PD patients than typical
treatment plans. Within the collaborative care approach, the GP treats the patient with
collaborative effort from a consulting psychiatrist and/or other trained care managers,
such as psychiatric nurse or psychologist. The collaborative care effort as found in the
reviews included many combinations. The reviews found that with collaborative care
methods the GP may or may not prescribe antidepressants with consultation with a
psychologist. In regard to psycho-education, the group found that a collaborative
psychiatrist with assistance from a trained care manager developed and implemented
the interventions for the participants that may include one-on-one interventions as well
as computer-based cognitive behavior therapy. The group also identified some studies
in which medication therapy in conjunction with psycho-education were utilized with a
combined effort of the GP and the consulted psychiatrist. These studies implied that
with collaborative care approach promising improvements may be seen in anxiety
disorders (especially in the USA) (Muntingh et al., 2014).
Muntingh et al. (2014) stated that their research found no studies in which the
collaborative care approach to GAD and PD involved a stepped care approach. Stepped
care approach as identified by the researchers is a least invasive and cost-effective
intervention that promotes self-management of GAD and PD. The researchers
identified the concerns about initializing antidepressants later for anxiety disorders.
With stepped care, medications would be a later step in the treatment plan for GAD and
PD after psychological interventions were utilized first.

The researchers stated that the

stepped care had received some validity as the National Institute of Clinical Excellence

for GAD and PD guidelines now include the stepped care method (Muntingh et al.
2013). Even with the acceptance as a promising approach to GAD and PD treatment,
there have been no studies as to the effectiveness of CSC in GAD and PD treatment. To
answer the questions of CSC effectiveness, the group conducted a study in which the
effectiveness of CSC treatment of GAD and PD were measured against the
effectiveness of CAU treatment of the disorders.
do evaluate the possibilities, the researchers developed a CSC model using 3
identified interventions from their research efforts into primary care setting. The three
that the group chose to incorporate in their study was guided self-help as a first step
approach, cognitive behavioral therapy as a second step, and antidepressant medication
as a third step if needed. The study's objective was to compare the effectiveness of
utilizing CSC treatment model versus CAU treatment for DSM-IV diagnosis of GAD
and PD.
The study was conducted in 43 primary care facilities with 63 physicians, 31
psychiatric nurses, and 6 consulting psychiatrists. Each psychiatric nurse had
established contracts with one or two of the 43 selected facilities. The clusters utilized
for this study consisted of patients in the study that were previously served by the
psychiatric nurse at the same facilities the patients were already using. The 31 nurses
were then assigned a group of patients using an automated random sequence obtained
from an established algorithm (Muntingh et al. 2013). The process developed an
intervention group that had 23 facilities served by 16 psychiatric nurses and a control
group that had 20 facilities which had 15 psychiatric nurses to serve the patients. The
recruitment of patients was an 18-month process that utilized two methods of

determination. The first method involved patients that were selected by participating
GPs of whom were patients that the GPs encountered with anxiety disorder issues. The
second method involved patients selected by research assistants from electronic medical
records who had previously seen the participating GPs in the past 4 months for
symptoms possibly related to anxiety disorders. From these groups, participants were
screened with a Patient Health Questionnaire anxiety module (Muntingh et al. ,2014).
All participants who screened positive were then contacted and participated in a phone
interview process by an independent research assistant who was kept blind to group
assignments. This interview consisted of a MINI-PLUS International Neuropsychiatry
Interview, a short form diagnostic interview process to detennine DSM-IV and ICD-10
psychiatric disorders to define inclusion or exclusion in the study (Muntingh et al.,
2014).
From the inclusion/exclusion parameters, 183 patients were included in the
study. Of the 183 patients, 114 were grouped into the intervention group (CSC), and 66
patients were grouped into the control group (CAU). The mean age of participants was
46.5 years, and the majority (68%) were female. To detennine outcomes, the study
utilized the Beck Anxiety Inventory (BAI) at the baseline of the study and again at 3. 6,
9. and 12 months. Data from these questionnaires were compiled and processed by a
research assistant who remained blind as to whether participants were in the control or
intervention group. In addition to the BAI, the researchers also administered the
Overall Anxiety Severity and Impairment Scale questionnaire (OASIS) at the start of
the study to have as a proxy if needed. The goal of the study was to detennine if
utilizing CSC in the treatment of GAD and PD reduced anxiety symptoms based on the

BAI score. A secondary outcome measurement was the time to first remission as
identified by a BAI < 11 on the scale. In addition, the group wanted to identify the time
it took for first positive response to the treatment if no remission was found. To
maintain consistency, the study also assessed an adherence to treatment and control of
care checklist to all GPs and care managers of the participants in the CSC group. This
checklist ensured that CSC components of treatment were utilized and that proper
monitoring with the BAI was being conducted. A CAU checklist was also created to
provide data about types of care, medications, and referrals that were offered for each of
the CAU participants.
To ensure that the intervention group treatment had consistency with
methodology, the psychiatric nurses were trained in a 3-day workshop that trained the
nurses in the collaborative care methods of guided self-care and cognitive behavior
therapy. The GPs were provided a 3-hour workshop on collaborative care, recognition
of anxiety disorders, and the prescription algorithm for antidepressant medications. In
addition, the 6-consulting psychiatrists were also educated in the CSC model,
prescription algorithm, and the consultation process. Within the CAU model, the
providers and nurses received no additional training and followed the Netherlands
national primary care treatment guidelines for anxiety (Muntingh et al., 2014).
After completion of data analysis, Muntingh et al. (2014) found a significant
difference in BAI score reduction with the CSC group as compared to the CAU group at
3-, 6-, 9-, and 12-month follow up screenings. This finding answered the primary
outcome measure as proposed by the research group. With the secondary outcome
measure, the study found that there were no significant differences between the CAU

group and the CSC group as pertaining to length of time required for first remission or
the length of time required for first response to treatment. In addition, the study found
no significant difference in the number of participants who either had no response to the
treatment or never achieved remission. Data from the adherence to treatment and
content of care in CSC checklist showed that half of the CSC participants had achieved
remission after guided self-help intervention and that 12 received referral to a
psychiatrist. For the CAU group, the content of care checklist showed that 27% of the
participants received antidepressant medications, 16% were referred to mental health
care specialists, 13% were referred to primary care psychologist. 12% received
counseling by either GP or psychiatric nurse, 8% were given antidepressants and
referred, and 24 % refused or had no desire for mental health treatment (Muntingh et al.,
2014).
The study indicated that CSC did provide reduced anxiety symptoms more often
than the CAU model in this study. The researchers concluded that the largest
difference between the two models of care came at the 12 months post baseline scores
which pointed to the conclusion that anxiety worsened in CAU participants and
remained improving with the CSC participants. With the second outcome
measurement, the study found no great difference in response and remission rates. The
researchers identified that a large part of the CAU participants either did not improve or
had worsening symptoms and that fact may explain the reasoning for no difference.
A strength of this study was the utilization of professional working care managers
throughout the study. By utilizing working care providers, the study was performed in a
natural health care setting in which the participants as well as care providers were

comfortable with and mirrored everyday practice events. Another strength was the
stud\ s use ot multilevel analysis and its avoidance of variability with the healthcare
professionals. Muntingh et al. identified several limitations to this study with the first
being differences at baseline within the two groups. Even with the randomized clusters
CSC participants had a more severe anxiety and took less antidepressants at the start of
the study than those in the CAU group. Another identified limitation was that the study
relied completely on self-report and not utilizing a combination of self-report and
clinical judgment. The researchers also identified that even though special attention
was given to train GP and care managers in the stepped care model, the implementation
could have been better. Data that showed a low rate of participants who continued to
the second step suggested that possible additional steps may be needed to optimize
participant participation. The researchers also identified areas for future study and
improvement for the area of study. The group suggested that future studies offer
participants choice in what method they would receive such as self-help options (e.g.,
exercise training, internet-based CBT, or guide books to utilize with the sessions in the
clinic). The group also suggested future study of the cost effectiveness of the CSC
model to establish feasibility of the treatment plan.
Muntingh et al. (2014) provided relevance to the current study by providing
clinical data in the management of general anxiety disorder. It was the goal of the
current researchers to determine if primary care providers in northern Mississippi are
utilizing best practice methods in the treatment they deliver to their patients. With
proposed new guidelines in limiting benzodiazepines as a first-choice method in

management of anxiety disorders, practitioners will need to find alternative tools in the
management of GAD that best treat their patients.
Gauidreau, Landreville, Carmichael, Champagne, and Camateros (2015)
performed a study to determine the acceptability of cognitive behavioral therapy (CBT)
in patients diagnosed with GAD. The first-line treatment of GAD involves Selective
Serotonin Reuptake Inhibitors (SSRIs) and benzodiazepines; however, SSRIs have
many adverse effects including fatigue and somnolence. The anxiolytic action of SSRIs
is often slower than the action of the benzodiazepines and hinder the long-term
observance of the illness. GAD is often undertreated in the elderly, and oftentimes the
elderly population will not seek help from healthcare professionals. The American
Journal of Geriatric Psychiatry stated that only 18% to 20% of older adults affected will
seek help from healthcare professionals. This issue is a new and rising topic for
treatment of GAD. No clear theoretical framework was identified for guidance of this
study.
Gaurdreau et al. (2015) evaluated the rate of acceptability in psychological vs.
pharmacological therapy, more specifically evaluating CBT, CBT-GSH (Guided SelfHelp) and SSRIs. Gaurdreau et al. identified an hypothesis that stated. "CBT would be
more acceptable than pharmacotherapy" (p. 69). The sample consisted of participants
from social/leisure clubs, retirement homes, day centers, and a medical clinic. A total
of 458 individuals were approached about participation, 205 agreed to participate, and
only 88 completed the questionnaire.
Persons in charge at day centers, social/leisure clubs, and retirement centers
were approached for consent in regard to recruitment. They were asked not to include

anyone with significant cognitive deficits. In medical clinics, brochures were left in
waiting rooms with information to contact the primary researcher if interested in
participation.
Atter a biiet discussion ot the study's objective and procedure, signed consent
was obtained. Participants were given an identification sheet, the Geriatric Anxiety
Inventory (GAI) and the Generalized Anxiety Disorder seven item scale (GAD7) used
to measure the severity of the symptoms of anxiety. Included also was the Penn-State
Worry Questionnaire (PSWQ-A). This tool is used to assess worry, which is a common
symptom associated with GAD. Also included was the 15-item Geriatric Depression
Scale (GDS) used to assess and measure depressive symptoms. Three copies of the
Treatment Evaluation Inventory (TEI) were included to evaluate the treatments
(descriptions included) used during the case study. Clinical characteristics were
collected in the identification sheet including episodes of anxiety during lifetime,
experience of treatments for anxiety during lifetime, and knowledge of what causes
anxiety attack. Participants were asked what degree of various elements (e.g., cost, side
effects, convenience, acceptability) could influence their choice of treatment for GAD.
This was asked on an 11-point scale ranging from no influence to very large influence.
The Treatment Evaluation Inventory was a tool used to measure treatment
acceptability. Eight items in this tool evaluated the positive aspects, general
acceptability (GA, 8). and three items identified the negative effects (NE, 3). The two
subscales were analyzed separately.
Analysis of the data showed that the average age of the participant was 74 years,
and the majority of the persons participating had minimal health issues requiring

medical attention.

Almost half reported having an episode of anxiety in their lifetime

and less than halt leported seeking medical attention for the anxiety. For the ones who
leported seeking medical attention for the anxiety, most reported receiving
pharmacotherapy. Knowledge and education regarding causes of anxiety were low
among the overall population. Participants who stated that they did not know what
caused an anxiety disorder rated treatments more unacceptable than individuals who
indicated that they did understand the cause of anxiety. The factor that had the most
influence on treatments tor anxiety was the doctor's recommendation, followed by side
effects, inconvenience, and acceptability. The researchers noted that this is especially
important in light of primary care providers" low recognition, treatment, and referral
rates for older patients with GAD (Muntingh et ah, 2014).
The average score on the TE1 was 44, which indicated moderate acceptability.
The results significantly differed by treatment type, but not GAD severity. Results
showed that older adults find all three GAD treatments at least moderately acceptable.
This information is in line with results from research including younger adults. The
results supported the hypothesis and was consistent with other results from research
with younger and older adults. When comparing CBT and GSH, CBT was more
favorable, which is interesting because they share the same principles and techniques.
It was noted, however, that CBC-GSH was more favorable when SSRI negative
treatment effects were taken into consideration. Muntingh et al. (2014) noted an
implication to the study would likely be that the under-treatment of GAD in older
persons is unlikely due to the perceptions of treatment of GAD. Muntingh et al. noted
that other possible factors could be difficulty traveling and patient characteristics.

Raising public awareness and implementing better access to resources would help
increase treatment rates. Recommendations for future research was to evaluate
indi\ idual s treatment regimen during and between treatment to determine if they are
perceived as acceptable.
A stiength of this study by Muntingh et al. (2014) was that the different levels of
severity in GAD were addressed. Also, the treatment plans for the case study were
defined along with the side effects of the treatment. A weakness of this study was the
level of difficulty of the questionnaires. The elderly population may have had difficulty
filling out the forms. Another weakness was that the researchers had no way to evaluate
if the older adults actually read the case and treatment descriptions before they
completed the ratings. Another area that was noted was that the size of the sample was
small, and the participants were mostly non-anxious, healthy adults which limited
generalizability.
Muntingh et al. (2014) provided useful insight regarding the patient's perception
of CBT. This study supported our current research interest by shedding light on the
patients' acceptability of CBT, obstacles that may interfere with recommendation
regarding pharmacological treatment of GAD. and banners regarding CBT application
to treatment plan.
Bernard et al. (2018) used an observational study to assess the patterns of
benzodiazepine use in primary care for management of anxiety or depressive disorders.
There was no theoretical framework identified for this study. In the management of
anxiety disorders, benzodiazepines have been identified as one of the most prescribed
drugs for anxiety disorders. Clinical guidelines for management of anxiety disorders

state that benzodiazepines are indicated for short term use in the management of anxiety
disorders. However, studies have shown that patterns of long-term usage of
benzodiazepines are found for many patients. With long-term benzodiazepine use.
studies show that many side effects from benzodiazepine therapy have become
problematic. This study set out to identify benzodiazepine use patterns as prescribed by
primary care providers and the correlation of long-term utilization of benzodiazepines
for anxiety disorder management. This study utilized a sample size of 740 participants
who were gathered from 64 primary clinics and their patients that met the inclusion
criteria from the providence of Quebec, Canada. The study utilized a mental health
screening tool given in the waiting rooms of the 64 primary care clinics as its initial
contact with samples. From that contact, the study moved forward with the World
Health Organization World Mental Health (WHO WMH) tool and the Composite
International Diagnostic Interview-Simplified (CIDIS) to identify participants who met
diagnosis inclusion. Those participants who met diagnosis requirements as set forth by
the Diagnostic and Statistical Manual of Mental Disorders (4 th edition) (DSM-IV)
published by the American Psychiatric Association (APA) for Generalized Anxiety
Disorder, Panic Disorder, or Social Anxiety Disorder within the past 12 months were
selected to move forward with the T1 structured interview to define final participants.
Of the 4,506 participants who agreed to participate in the study, the T1 interview
produced the final participant count of 740 adults who met all inclusion criteria.
Bernard et al. (2018) examined benzodiazepine use patterns in primary care
patients suffering from anxiety disorder. In addition, Bernard et al. explored the
correlation of long-term benzodiazepine use in primary care patients suffering from

anxiety disoiders with sociodemographic factors, clinical factors (severity of anxiety
disorder, comorbid mental health conditions, and physical comorbid conditions),
medication factors (what class of drugs, sleep aide drugs), and visits for mental health
status within the past 12 months to mental health physicians or general practitioners
(Bernard et al., 201 8). Within the study, the researchers hypothesized that patients who
were prescribed benzodiazepines for short-term management for anxiety disorders for
known and unknown reasons remain on benzodiazepines for long-term therapy in place
of other treatment modalities. The researchers identified anxiety disorder as one of the
most prevalent mental disorders in the general population. This study utilized the
Canadian clinical practice guidelines for the management of anxiety, post-traumatic
stress, and obsessive-compulsive disorders as published by BMC Psychiatry. Evidencebased treatment guidelines for anxiety disorders identified benzodiazepines as effective
in treatment of anxiety disorders, but only as an adjuvant short-term option.
Benzodiazepines and their tendency to cause sedative/hypnotic effects,
dependence, and potential of abuse limit benzodiazepines to use for short-term
management only. Clinical practice guidelines for pharmacological management of
anxiety disorders state selective serotonin reuptake inhibitors (SSRIs) and serotonin and
norepinephrine reuptake inhibitors (SNRIs) are first-line

treatment for anxiety disorders

due to their safety and tolerability profiles. Despite benzodiazepines" short-term
definition, many studies have identified as many as one in four patients diagnosed with
anxiety disorders could be using benzodiazepines for long-term therapy.
The study found 4,506 participants who agreed to participate in the study
initially; after inclusion and exclusion properties were assessed, 740 participants were

identified for the final sample size. The inclusion criteria required participants to meet
the following, (a) age 18 years or older, (b) consult a primary care provider for
themselves, and (c) ability to complete the questionnaire. The questionnaire included
self-reported status of sociodemographic characteristics, overall health status, primary
care provider, psychotropic medications, and chronic health issues. In addition.
Hospital Anxiety and Depression scale (HADS) and the World Health Organization
Disability Assessment Schedule 2.0 (WHODAS 2,0; self-reported 12 item version)
were part of the questionnaire. With completion of the surveys, participants who were
patients at one of the participating clinics and who met at least one of the final inclusion
standards were invited to participate in the telephone/web interview. The final inclusion
standards were as follows; (a) current anxiety or depression symptoms, (b) anxiety or
depression medication in the past 12 months, (c) depression or anxiety diagnosis made
by a physician, and (d) consulted for mental health issues within the past 12 months
(Bernard et al., 2018). After the original screening, the interview portion of the
methodology began. The interview process consisted of completion of the CIDIS by a
lay-interviewer, a review of each patient's experiences with past care provided,
medications, and self-identified status of mental health. The medication usage was
broken down in two parts with the first section consisting of usage of medications either
prescribed and/or over-the-counter for anxiety, depression, sleep issues, mood
stabilization, psychotic disorders, and stimulants. The second part of the medication
screening was completed for those who indicated yes to anxiety or antidepressant
medications. In this section participants were assessed for name of medication, dosage,
doses per day, PRN or daily use. duration of therapy and last follow-up visit with the

presciiber. The final sample produced 740 adults meeting the criteria for GAD or social
anxiety disorder during the previous 12 months of the survey. Bernard et al. (2018)
defined the study participants as those who utilized at least one benzodiazepine with
evidence-based recommendations for any of the anxiety disorders as defined by
Canadian Psychiatric Association s (2006) clinical practice guidelines. In defining the
tenn long-term benzodiazepines. Bernard et al. stated long-tenn was any utilization of
benzodiazepines tor a period > 12 weeks which included regular and as-needed use. In
finding potential correlates of long-tenn benzodiazepine use, sociodemographic factors
of age, sex. education level, marital status, economic situation as described by
participants, and self-pay or insurance coverage for the cost of care including
medications cost were categorized. Data were also stratified to take in account clinical
factors, such as patients' perception of their mental health, comorbid major depression,
severity of their anxiety and depressive symptoms, medications for sleep disorders or
other psychotropic drugs prescribed with evidence-based recommendations for anxiety
disorders, and consultation for mental health services within the past 12 months.
After data collection, the study found that 76% of the participants were female
and the mean age of participants was 42.6 years. Education level of the participants
showed that 49% of participants had at least a college or university education. Over
30% of participants reported their economic status as being poor or very poor. Over
50% of participants were either married or living with a partner. Of the total sample,
83% reported having a family physician, and 66% reported they had access to insurance
that covered medications and/or health services. Data also revealed that participants
were prescribed benzodiazepines both short-term and long-term, recorded HADS-

anxiety score in the abnormal category with a score of 14.1 for short-term usage and
12.1 tor long-term users showing that benzodiazepines did very little to reduce the
participants anxiety disorder. Data also showed that of the total sample 38.8% had at
least three comorbid chronic physical conditions. The study did show that 86.1% of
those identified in the sample have had at least one visit with a family physician for a
mental disorder within the 12 months preceding the study. Data also identified
e\ idence-based recommended drug class usage as follows: Benzodiazepines, 22.6%;
SSRI, 27.4%; atypical antipsychotics, 8.9%; 4.5%, monoamine oxidase inhibitors; 2%
for tricyclic anti-depressives and anticonvulsants; and 25% for other agents.
Benzodiazepine use as reported in the survey shows 22.6% of those surveyed
had utilized benzodiazepines within the past 12 months in their treatment of their
anxiety disorders and that included both regular (daily, BID. TID, etc.) and as needed
utilization (PRN). Of those identified, 88% met the parameters as set by the survey for
long-term benzodiazepine use. Of those identified as long-term users, those 30 years
and older were much more likely to use benzodiazepines as a long-term therapy. Those
aged 45 years or greater made up over two thirds of long-term users; of that group,
those aged > 60 years made up a large portion of those found. With the data, the study
showed that, of those prescribed benzodiazepines for treatment for their anxiety
disorder. 88.4% of them were long-term benzodiazepine users for anxiety which
indicated inadequate use of clinical practice guidelines by primary care providers. This
study has shown that there is a public health concern for the inadequate use of
benzodiazepines as many times short-term regimens morph into long-term usage and
with long-term use comes serious implications of abuse/dependence potential, rebound

and recurrence symptoms, and the adverse effects of benzodiazepine withdrawal.
Bernard et al. (2018) also showed that many times those who are on long-term
benzodiazepine therapies are the elderly population and those who have comorbid
considerations as well. Benzodiazepine use has long been associated with increased
risks for falls and fractures within the elderly population and many times affect mobility
and activities of daily living. Another finding of the study was that many of those
currently utilizing benzodiazepines were also prescribed SSRIs. Many times SSRIs
produce side-effects, and benzodiazepines are indicated as an adjunctive therapy for
treatment of these side effects. Benzodiazepines are also indicated in an acute crisis
state or while waiting on the SSRI to reach efficacy rate but always for a short-term.
Another finding by Bernard et al. (2018) was that many times those identified with
anxiety disorder along with a diagnosis of major depressive episode were prescribed
benzodiazepines as a monotherapy for which there is no evidence-based guidance that
benzodiazepines are effective for depressive symptoms. The study found that in clinical
practice benzodiazepines can be useful tools in the management of anxiety disorders,
but the use of long-term benzodiazepines can promote the opportunity of poor outcomes
for many patients. General practitioners should consider identifying those at a high risk
for prolonged use and consider this in their planning, management, and prescription
activation. General practitioners must explain to patients in detail the adverse effects of
benzodiazepines, such as risks of motor vehicle accidents, fall risks. ADL possible
limitations, amplified effects associated with alcohol use, dependence risk, tolerance,
and difficulty stopping the medication. Providers must also explain to patients that
benzodiazepines are prescribed for short-term use only and should be discontinued after

acute episodes are under control or alternative drugs have reached their effective levels.
Patients are to be closely followed, and benzodiazepine use is to be closely reviewed
whether acutely or when long-term use cannot be avoided and consider discontinuing
benzodiazepines at each follow-up visit. Results found by Bernard et al. (2018)
indicated there is a need for continued clinical awareness of this problem, and patients
need to be informed of the risks and prevalence of long-term benzodiazepine use in
anxiety disorders when making decisions about their pharmacological treatment of their
anxiety disorder. In the study, Bernard et al. (2018) discovered many patients with
comorbid conditions along with their anxiety disorders impacted clinical providers'
decision making in the use of benzodiazepines within this group of patients. This
unexpected result led researchers to conclude that a future study to better understand
prescriptive decision making within this sub-group and perhaps other studies was
needed at this time.
The strength of this study by Bernard et al. (2018) was the large sample size in
which data were collected. This study is one of the largest of its kind in a primary care
setting. Primary care providers are usually the first contact that patients have with
management of anxiety disorders. A strength of this study was the data showed that
benzodiazepines are being prescribed outside clinical guidelines, and many times may
be at the expense of the patient's well-being, especially those > 60 years old. The
correlation established between long-term benzodiazepine use and the prescribing of
benzodiazepines for anxiety disorders provided valuable data in finding a possible
solution to the problem of long-term benzodiazepine use. The study did have
limitations, such as the initial survey used to define potential participants was a self-

reported questionnaire that led to possible informational bias. Another limitation
identified was the distinction ot those who were prescribed or not prescribed
benzodiazepines for causes related to comorbid conditions. A third limitation was
identified in that the participants were initially screened by a lay interviewer who had
no previous medical and/or mental health caregiver status when given the initial
screening tools. By using non-professional healthcare interviewers, the possibility of
error could not be removed.
Bernard et al. (2018) was useful in the current research study entitled
Generalized Anxiety Disorder: Management practices among Primary Care Providers in
northern Mississippi. Data collected in this study represented the number of patients
who are being prescribed benzodiazepines as well as other pharmacological options in
the treatment of anxiety disorders. Data from this study was used as a comparison to
the current research project that will evaluate benzodiazepines prescribing among
primary care providers in northern Mississippi.
Vicens et al. (2016) assessed the efficacy of two interventions on discontinuing
benzodiazepines in patients who had been taking the medication long-term. The
purpose of this study was to assess the efficacy over a 3-year period. A previous study
with the same interventions had been assessed at the one-year cessation period. General
practitioners (GPs) mainly treat anxiety, insomnia, and sometimes as a substance that
enhances the treatment of depression with BZDs. Long-term use of benzodiazepines
(BZDs) is not recommended and can increase the risk of falls, impairment of cognition,
and as well as mortality. Even though these risks are well-known, many GPs continue
to prescribe BZDs as long-term therapy. Most GPs find discontinuing BZDs as

challenging and time-consuming so most do not develop any kind of withdrawal
intervention. There is supporting evidence that proves the interventions of structured
intervention with follow-up visits (SIF) or structured intervention with written
instructions (S1W) showed a reduction in the long-term use of BZDs at 12 months by up
to 30%. There was no theoretical framework identified for this study.
The research question Vicens et al. (2016) attempted to answer was the efficacy
ot SIF or SIW after 3 years. There is limited information about the long-tenn efficacy
of the discontinuation ot BZDs. Vicens et al. found that patients" effectiveness of
discontinuation of BZDs using SIF and SIW is just as strong at the 3-year mark as it
was at the one-vear mark. Even after 3 years, there were no changes in anxiety,
depression, and/or sleep noted after the discontinuation of BZDs using the two primary
care interventions.
This study by Vicens et al. (2016) was a multicenter, three-arm, cluster
randomized, controlled trial. The trial was earned out in three regions of Spain. Each
region enrolled 25-30 GPs for a total of 75 GPs who were divided randomly to one of
the three regions. A total of 532 patients were recruited by the GPs from November
2010 to February 2011. The randomization of the recruitment process was conducted
by computerized prescription databases located in primary care offices. The guidelines
that were adhered to were the patients had to be between the ages of 18 and 80 years,
had to read and speak Spanish, and had to be taking BZDs every day for at least 6
months. Excluded from the study were patients with the diagnosis of psychotic
disorder, severe personality disorder, alcohol or illicit drug abuse, anxiety or depressive
disorder currently being treated by a psychiatrist, severe medical or tenninal illness or

currently hospitalized. Patients were also excluded if the GP believed that cessation of
BZD use may be harmful and if they were unable to read and speak Spanish" (Vincens
et ah, 2016). The patients were randomly divided into the three groups of study. The
groups were S1F. SIW. and usual care.
After the GPs were randomly allocated, those that were to be involved in the S1F
and SIW amis attended a 2-hour workshop on the discontinuation of BZDs. The S1F
and SIW were both given educational interviews with information regarding stepdown
therapy of their BZDs. The educational interview had four key points:
. . . information on BZDs, dependence, abstinence, and withdrawal symptoms;
the risks of long-term use, and effects on memory, cognitive impairment,
accidents and tails; reassurance about reducing medication; and a self-help
leaflet to improve sleep quality if patients were taking BZDs for insomnia.
(Vincens et ah, 2016, p. e86)
The S1F group followed up with their GPs every 2-3 weeks to have their dose
tapered until their stepdown therapy was completed. The SIW received written
instructions on how to gradually taper their dose until their stepdown therapy was
completed without follow-ups with their GPs. The gradually reduced dose of BZDs
consisted of a 10-25% reduction of daily dosages every 2 to 3 weeks. Patients in the
usual care group were given routine care, and the GPs were not given any guidelines on
managing their patients' long-tenn BZD therapy.
The primary goal for all groups was BZD cessation. BZD cessation was defined
as no prescription for 6 months or < 30 doses in the whole 6-month period. There were
also secondary outcomes measured which included the measurement of the presence of

anxiety, depression, and sleep satisfaction. The primary goal was assessed by clinical
researchers who evaluated clinical records for prescription claims. The secondary
outcome was measured by the Hospital Anxiety Depression Scale (HADS) which
measuied anxiety and depression symptoms from no symptoms to severe symptoms.
Sleep satisfaction was measured on a different scale, the Oviedo Sleep Quality
Questionnaire, which measured sleep satisfaction on a scale from not satisfied to very
satisfied The statistical approach used for this study consisted of evaluating the sample
size at the beginning, at the end of one year, and at the end of the 3-year period. BZD
discontinuation was based on an intention-to-treat analysis and was analyzed at the end
of the 36 months. Following statistical analysis, it was found that the average age of
patients was 64 years old and 72% female. There were 35 patients who did not follow
up at 12 months and a total of 86 by 36 months. However, the prescriptions were still
able to be measured for 506 patients with 26 lost to follow-up related to the fact that
prescription claims were in clinical records.
At 36 months, 66/168 patients (39.2%) in the S1W group. 79/191 patients
(41.3%) in the SIF group, and 45/173 patients (26.0%) in the control group had
discontinued BZD use. A total of 131/188 patients (69.7%) who successfully
discontinued BZD use at 12 months remained abstinent at 36 months. The
groups showed no significant differences in anxiety, depression, or sleep
dissatisfaction at 36 months. (Vicens et al., 2016, p. e89)
Vicens et al. (2016) identified several strengths of the study. First, the study
evaluated efficacy over a long period of time and used a large randomized study group.
The study also had a high internal validity with few patients being lost to follow up.

treatment. Landreville et al. (2016) proposed a solution to the problem of undertreatment by developing a guided self-help therapy using CBT for elderly patients to
use remotely. Landreville et al. did not credit a theoretical framework with guiding
their research.
The main objective of the study was to determine if a cognitive behavior therapy
with guided self-help (CBT-GSH) would be effective in reducing GAD symptoms
among older adults. Justification for the study was given from another research study
which concluded that cognitive behavioral principles could be advantageous over
medication for treatment of GAD. A convenience sample was used based on
advertisements in sociocultural and health centers in an undisclosed location.
Participants were selected based on eligibility criteria of the following key variables:
age > 65 years, diagnosis of GAD, literacy, ability to use a telephone, agreement to
attend face-to-face meetings, and agreement not to change any pharmacologic treatment
for GAD during the study. Excluding criteria for the sample included substance abuse
disorders, uncontrolled physical disorders, psychosis, cognitive impairment, and other
concurrent psychotherapy treatment for GAD.
Altogether. 29 individuals agreed to be contacted regarding participation in the
study. Of these, 5 declined to participate following initial contact, and 9 were excluded
due to criteria. Following a diagnostic interview, 11 individuals were further excluded.
Of the remaining 4, one withdrew due to lack of time. The study was then conducted
among 3 adults, ages 66 to 70 years. Data were compiled through self-report inventory.
For pre-evaluation, each participant was given several questionnaires to evaluate the
severity of their GAD symptoms as well as surveys related to depression and insomnia,

considered relevant to a GAD diagnosis. In total. 13 self-administered questionnaires
were used to evaluate participants' symptoms, all of which are established assessment
tools related to anxiety, depression, and aging. The treatment was then conducted over
15 weeks. Each subject was given a manual with CBT-GSH material covered in eight
modules. For each module, the participant was asked to read the corresponding
material in their manual, complete the exercises, and then return the booklet via mail at
the end of the week. The material was then reinforced with a weekly 30-minute
telephone session with a therapist. Additionally, the therapist and each subject met
tace-to-face once at the beginning and at the conclusion of the treatment. The sessions
with the theiapist were considered supplementary to the primary material from the
manual. The pre-treatment questionnaires were repeated during treatment and at 6- and
12-months post-treatment.
Data analysis came from the results of the questionnaires. Participants'
responses from each questionnaire were evaluated to see if they improved from clinical
(responses indicating GAD) to non-clinical (indicating the absence of GAD). The
researchers classified the results into three categories: time spent worrying, GAD
severity, and the participants' evaluation of the treatment. In the first category, all
subjects experienced marked and stable reduction of time spent worrying following
initiation of treatment, although one subject briefly showed an increase in time spent
worrying at onset. In the second category, GAD severity, a clinically significant change
was seen among each participant from questionnaire scores at the end of treatment. The
post-treatment scores of GAD severity were maintained at 12 months post-treatment for
two participants, but the third had a return to pretreatment scores. The third category of

results, participant evaluation of treatment, showed generally positive regard for the
CBT-GSH tool. Feedback suggested that the telephone therapy sessions be longer, the
treatment extend beyond 15 weeks, and that the manual be reorganized. Notably,
although the authors summarized the participants' scores in a table and line graph, no
statistical analysis was performed beyond a Reliable Change Index.
The researchers concluded that the CBT-GSH tool is feasible and effective for
treatment of GAD among older adults. Specifically, the CBT-GSH tool was found to
diminish worries and the overall severity of GAD among the participants. The
researchers acknowledged the limited generalizability of the sample to the overall
targeted population, particularly given the younger ages of the participants and
relatively good physical health compared to the geriatric population at large.
Landreville et al. (2016) recommended future randomized controlled trials with the tool
among a larger and more diverse sample to definitively evaluate if the GSH-CBT tool
could be a first-line treatment for older adults with GAD.
Landreville et al. (2016) compellingly presented the need for improved
modalities of treatment for geriatric GAD patients. Landreville et al. outlined well the
need for increased recognition and active treatment of GAD, as well as acknowledging
the harsh realities of obstacles for treating this age group, such as lack of resources,
limited mobility of patients, etc. In response to this need, remote CBT-GSH seemed an
appropriate form of treatment. Landreville et al.'s research was extensive and limited to
primary sources. The nature of the data collection through self-report reduced the risk
of bias and contributed to the trustworthiness of the study.

However, there were weaknesses in Landreville et al. (2016) which reduced the
credibility of the researchers conclusions. The most significant weakness of this study
was the small sample size. Although the subjects were thoroughly vetted for eligibility
criteria, the small number inherently diminished generalizability of the study.
Moreover, the data analysis was tedious to review due to the lack of conciseness. Meta
analysis of questionnaire results would provide more succinct and categorical results,
although meta-analysis is likely impossible without a larger sample size. The authors
did not well define some of their operational tenns. including GAD nor did they define
what ages comprised the population of older adults.
Landreville et al.'s (2016) study is relevant to the current research. First, this
study reinforces the notion that CBT is effective as a treatment for GAD. Second, this
study provided a solution to the problem of accessibility to CBT. Often patients cannot
afford the cost or time to partake in CBT, or CBT-trained clinicians are prohibitively far
away or do not have openings for new patients for weeks to months. For the geriatric
population, mobility and resources for transportation to a CBT clinic are of special
concern. For these reasons, the implementation of a self-help manual with telephone
sessions could increase accessibility to CBT for the broader population.
Maust. Kales, Wiechers, Blow, and Olfson (2016) conducted a study to address
the issue of benzodiazepines being prescribed to older adults. Despite
recommendations for guarded prescriptions, many primary care providers continue to
prescribe Benzodiazepines for older adults, and the risk associated are often detrimental
to the patient. Many times the side effects with benzodiazepines are often brushed off
to elderly age behavior, such as increased risk for falls, increased risk for motor vehicle

accidents, impaired cognition, and increased dementia. The researchers noted the
American Geriatrics Society (AGS) "recommended to avoid any use of benzodiazepines
for the treatment of insomnia and agitation" (p. 2546). Despite this recommendation,
one third of benzodiazepines are prescribed to older individuals. Maust et al. used prior
studies to help identify the problem at hand and used data from the National
Ambulatory Medical Care Survey (NAMCS). The information obtained from this
survey revealed clinical characteristics of patients and looked into how continuation of
benzodiazepines occurs. No obvious theoretical framework was identified.
The objective stated for the study was to determine how often benzodiazepines
are prescribed to the elderly population and to identify how often the length of treatment
is converted into long-term therapy. This study focuses on non-psychiatrist physicians.
The purpose for this study was to provide infonnation on the increased risk of
benzodiazepines in older adults and to identify recommendations for management.
Methodology used analyses from NAMCS from 2007-2010 for the sample
population. The survey included office-based physicians designed to include "objective
and reliable information for the use of ambulatory medical care services in the United
States" (Maust et al. (2016, p. 2547). The survey gives a physician a reporting period of
one week where he or she is to report the cases that come into the office. Diagnosis,
treatment, and medication are reported in the survey. Researchers looked specifically at
any medication in the category of benzodiazepines. Characteristics of the visit were
gathered for analysis including the following: (a) how many times the patient had been
seen in the office in 12 months, (b) whether or not the visit addressed a new or chronic
problem, (c) what patient complaints triggered benzodiazepine usage, (d) if any other

psychotherapy had been used in lieu of or in combination with benzodiazepines, and (e)
whether or not a follow up visit was scheduled or not. Analysis limited the results to
patients over 65 yeais old and used "logistic regression to test the association between
individual characteristics and benzodiazepine therapy" (Maust et ah, 2016, p. 2548).
The denominator used tor comparison of the proportion of benzodiazepine visits was
pulled from each age group from the U.S. Census. Benzodiazepine prescribing was
further compared by looking at type of prescribing—either new or a continuation of an
already active medication. Analyses were obtained through Stata version 13.1.
Outcomes of the study revealed that benzodiazepines usage increased with age,
and continuation increases with age as well.

A higher proportion of older adults using

benzodiazepines had increased chronic conditions, increased frequency of office visits,
and increased prescription medications. Results mentioned were benzodiazepines
prescriptions accounted for 5.6% of office visits or 20.4 million visits annually. Visits
for new benzodiazepine therapy were often void of a mental health diagnosis. This
finding led researchers to believe that oftentimes the prescribers were treating a
troubling life event or acute stressful time period for the patient. Alternative therapies
showed infrequent usage. Selective serotonin reuptake inhibitors qualify for first-line
pharmacological therapy for anxiety, yet only 25% of all benzodiazepine users were
taking an antidepressant. This finding suggested that the safest treatments for anxiety in
older adults are not being used. Cognitive behavior therapy was almost absent in newly
prescribed benzodiazepines with < 1% of all newly prescribed cases including referral
to psychotherapy or education for stress management. Despite growing evidence of the
risks and dangers of benzodiazepines use in older adults, therapy for anxiety with

benzodiazepines continue unabated. Maust et al. mentioned a previous study where
chronic benzodiazepine users were asked about alternative methods for anxiety
treatment, and the users reported doubt that it would help with symptoms and rejected
the idea ot psychological therapy. Reasons why benzodiazepine therapy is continued,
despite recommendations stating the risk, were discussed with providers; and the
majority reported that attempting taper and discontinuation would be time-consuming
and likely unsuccessful. Maust et al. (2016) noted that, as stigmas decrease for mental
illness, it is possible that older adults may consider psychotherapy in the future.
However, accessibility would be a concern in certain regions.
Strengths of this study included the large sample size and large geographical
location. The greater the sample and more diverse the area of data collection is the
greater the pool of information for statistical analysis will be. Several weaknesses did
present itself in the study. Clinical assessment of signs and symptoms of the presenting
condition were not reported. Visit diagnoses were limited to 3 per patient, so additional
information may have been present for clarification of benzodiazepine use or nonuse.
NAMCS did not clarify if the benzodiazepines were prescribed on a PRN basis or a
scheduled basis, and overestimation of usage could develop from this weakness.
NAMCS focused on office-based clinics so the physicians in other settings were absent
from the sample. Mentioned also was the focus of non-psychiatiic physicians and
whether or not the patient was being seen by a psychiatrist. It is possible that the
psychiatrist initiated the continued benzodiazepines. Psychotherapy or other alternative
therapies may have already been discussed or attempted.

Maust et al. (^.016) provided a strong foundation to build the current research
because the study helped address the current noncompliance of nonpsychiatric
physicians prescribing practices of benzodiazepines. Maust et al. (2016) mentioned
that new protocols and strategies are needed to encourage physician discontinuation of
inappropriate benzodiazepine usage. The usage of this way of thinking helped
strengthen the current research hypothesis.
Stanley et al. (2014) assessed developing a broader workforce of those who can
offer cognitive behavior therapy (CBT) to older adults that consisted of "lay providers
working under the supervision of licensed providers" (p. 392). The current study
consisted of evaluating bachelor-level lay providers (BLPs) working with licensed
providers and with no healthcare experience compared to experienced PhD-level
providers (PLPs) and usual care (UC) for CBT in late-life GAD. The growing need for
healthcare professionals trained in geriatric mental health care is increasing
exponentially. By 2030. "the growing number of older adults needing mental health
care is expected to reach 10-14 million" (Stanley et al., 2014. p. 392). GAD is
responsible for an increase in disabilities, comorbidities, memory loss, insomnia, and
depression. The purpose of this study was to assess the effectiveness of BLPs in
providing CBT to older adults with a diagnosis of GAD in hopes of broadening the
workforce of professionals who can provide such options. There was no theoretical
framework identified in the study.
The research question Stanley et al. (2014) attempted to answer was whether or
not CBT for GAD can be provided by BLPs under the supervision of licensed providers
and can be done effectively with positive results. Expected outcomes for the study

would be at the end of the 6-month trial the BLPs and PLPs group would have
improved GAD symptoms when compared to the UC group. "Recent literature reviews
and clinical trials suggest that psychosocial treatments of anxiety and depression
delivered by experts and nonexperts produce comparable outcome, with potential
economic and logistic advantages for nonexperts" (Stanley et al., 2014, p. 392).
The method of this study included 223 older adults with a mean age of 66.9
years with a diagnosis of GAD. Inclusion criteria for participation included a diagnosis
of GAD or co-diagnosis of GAD guided by the Structured Clinical Interview for DSMIV (SC1D). Participants spoke English and psychosocial or pharmacological treatment
was allowed. However, psychotropic medication had to be stable over the prior month.
The patients were recruited through two different primary care clinics by self-referral
and electronic medical records. They were randomly assigned to BLPs, PLPs. and UC
groups and assessed at baseline of trial and at the end of the 6 months. CBT in the
BLPs and PLPs groups included 3 months of skills training and 3 months of skills
review via phone or in person. Skills training included "up to 10 skill-based sessions,
including core (education, awareness training, and motivational interviewing; deep
breathing; coping self-statements) and eleetive skills (behavioral activation, exposure,
sleep management, problem-solving, progressive muscle relaxation, thought stopping
and cognitive restructuring) skills" (Stanley et al.. 2014, 393). Skills review consisted
of patients being "called weekly for 4 weeks and then biweekly for 8 weeks to reviewskills and provide support for continued practice and skills use" (Stanley et al.. 2014, p.
393). Patients expressing interest in the trial were asked screening questions in which
responding affinnatively led to an in-person visit where further screening was pursued.

Those with suicidal ideations, psychosis, bipolar disorder, recent substance abuse, and
cognitive impairment were excluded from participation.
Measures and data collection consisted of self-reported worry and anxiety along
with clinician-rated measures. An 8-instrument questionnaire and a 6-item scale were
used to measure the severity of worry phenomena in the GAD patients. Anxiety was
also measured by a 20-item, self-reported questionnaire as well as a structured interview
guide. Depression symptoms and insomnia were measured as a secondary outcome
using an 8-item health questionnaire and a 7-item self-report measure, respectively.
Physical and mental health was also measured as part of the clinical trial by using a 12item short form of study. Self-report questions included information regarding if and
what kind of medications were used prior to the 3 months of the study that included
anti-anxiety meds and/or antidepressant meds.
The first group consisted of 5 BLPs who were all females with bachelor's
degrees in a relevant field (e.g.. psychology, sociology, etc.) who worked on the project
one to 2 years. Their mean age was 25.6 years, and they had no previous training in
mental health or late-life anxiety. Their training included reading, didactics, reviewed
audiotapes of expert sessions, and role play. The second group consisted of 5 PLPs
who were all women with a mean age of 30.8 years who worked on the project for one
to 3 years. They were postdoctoral fellows who had previous training in CBT. Prior to
the project, PLPs received training and gained experience in CBT through research and
graduate schooling. CBT sessions for both groups occurred over 6 months and used
skilled-based sessions and skilled review. The sessions were recorded and the results of
the trial did not differ significantly between the BLP groups and the PLP groups.

A data analysis w as gained from examining the differences between the groups
at the end of 6 months. Randomized group individuals were found to be more educated,
white men, with a higher income than the nonrandomized group. A total number of 43
patients diopped out with higher rates in the BLP and PLP groups than the UC group,
but this did not interfere with the study results. The characteristics of the treatment
between PLPs and BLPs showed no differences and showed improvement in patients
receiving CBT when compared to those just receiving UC. It was found, at the end of
the 6 months, that patients did not have to increase the dose of their antianxiety or
antidepressant medications nor did they add any antidepressant medicine if they were
not previously on these medications. By the end of the 6 months, the study actually
showed a reduction or discontinuation of such medications. Results showed that GAD
improved with CBT in both BLP and PLP groups, and GAD improvement was higher
in these groups when compared to UC. The study supported "evidence-based mental
health care supervised by licensed providers'' (Stanley et al.. 2014. p. 398) which can
expand on the need for a bigger workforce for mental healthcare. This type of
discovery may actually "bridge the gap between evidence and practice that plagues
current care models" (Stanley et al., 2014, p. 398).
Stanley et al. (2014) reported that training procedures provided by providers
produced competent lay providers who had no prior healthcare experience. A reported
strength of this study was the trained lay providers were able to provide positive
treatment outcomes for both BLP and PLP groups. A limitation of the study is the
different backgrounds of socioeconomic status in the randomized groups versus the
nonrandomized groups. Also, one of the instruments used for treatment was shortened

from its original veision as well as there were no clear guidelines as to how GAD was
actually diagnosed. The study was also limited by not clearly defining usual care.
This study was relevant to the current research on generalized anxiety care
among primary care providers in Mississippi. "This study paves the way for future
effectiveness and implementation trials of CBT for late-life GAD in other practice
settings, including community-based service agencies in which a range of providers
could learn to deliver CBT (Stanley et ah, 2014, p. 399). Other issues defined were
requirements and costs of preparation of providers and adequate supervision and
consultation of the anxiety treatment approach. This information is important to
funding the expansion of nonexpert providers delivering CBT in all service settings as
well as primary care offices. This study gives insight into the shortage of primary care
providers with time or resources to conduct CBT as a treatment option for GAD and
gives insight into other possible options that could be considered to deliver CBT. A
possible limitation to the current researchers' project would be few referrals to CBT
possibly because of limited resources available in the northern Mississippi area. This
research by Stanley et al. (2004) expanded on the use of lay providers, including
community providers, as a possible option for delivering CBT.

C H A P T E R III
Design and Methodology

Benzodiazepines typically are not first-line

treatment in the management of

anxiety and are not recommended for long-tenn therapy. However, the prescription of
benzodiazepines often does not comply with treatment recommendations.
Psychological therapies are recommended as first-line therapy but are often
underutilized (Maust et al„ 2016). The researchers sought to identify the management
practices of GAD F41.1 and Anxiety disorder, unspecified F41.9 among healthcare
providers in northern Mississippi clinics. The researchers sought to determine therapy
utilized by providers in five northern Mississippi primary healthcare clinics, including
pharmacological and nonpharmacological therapy. If therapy included
benzodiazepines, the length of time therapy was prescribed and reviewed.
Design

The researchers utilized a qualitative, descriptive design using retrospective
chart review to determine management practice of anxiety among healthcare providers
in northern Mississippi. A data collection tool was designed to organize data (see
Appendix A).
Setting

Five clinics were chosen, all of which provide primary healthcare services to
patients of all ages. The clinics chosen were located in northern Mississippi. Each
participating clinic was staffed with at least one primary care provider (PCP) as well as
support staff.

Population and Sample

The target population tor this study included male and female patients 18 years
of age and older with a diagnosis of GAD and/or Anxiety disorder, unspecified. A
convenience sample was used. A total of 498 charts were selected that met the above
requirements. Data for this study were gathered through retrospective chart reviews,
thus no human subjects were used.
Methods of Data Collection

Prior to data collection, approval was obtained from the Mississippi University
for Women (MUW) Institutional Review Board (IRB) to conduct the study (see
Appendix B). After approval from the IRB. each researcher obtained informed consent
from each family practice clinic's office manager (see Appendix C). The consent
allowed each researcher to access medical records for the purpose of assessing the
management practices of practitioners in relation to patients diagnosed with an anxiety
diagnosis. Methods of access to medical records did not vary from clinic to clinic.
Each researcher negotiated the use of temporary pass words to access electronic records.
Empirical data were collected regarding the treatment of GAD F41.1 and Anxiety
disorder, unspecified F41.9, the duration of treatment, and follow-up. To protect
confidentiality, empirical data did not include any patient or clinic identifiers. Data
included age, gender, race, payer type, marital status, provider type, diagnosis, any codiagnoses. treatment prescribed to the patient, length of treatment, and whether or not
education was provided regarding titration or cessation of benzodiazepines. Three
treatment types were documented: pharmacologic, non-pharmacologic, or both.

Pharmacologic treatments were broken down into benzodiazepines, SSRls, both, or
other.
The data collection worksheet was utilized by each researcher to document the
findings.

Data were collected during normal business hours at the participating clinics

and under staff supervision. Data were transferred to a spreadsheet for analysis, and the
spreadsheet was housed on a password-protected computer and jump drive. At the
conclusion of the study, all collected data were destroyed.
Methods of Data Analysis
The researchers designed the data collection worksheet for the chart review.
Once all data were collected and entered onto a spreadsheet, descriptive statistical
analysis was conducted. The data collection worksheet included the following
information: age in years, gender, race, payer type, marital status, provider type,
diagnosis, co-diagnosis, treatment, pharmacologic treatment, how long benzodiazepine
treatment lasted, education or discussion regarding titration or cessation of
benzodiazepine treatment, titration down or cessation of benzodiazepine treatment, and
non-phannacologic treatment type. Data were subjected to analysis using descriptive
statistics including frequency distribution and percentages. Data were then analyzed for
physician adherence to state medical board prescriptive regulations.
Disclosure
No incentives whatsoever were provided to the clinics to participate in this
research. At the conclusion of the study, a letter thanking each participating clinic was
delivered expressing the researchers' appreciation for their cooperation (see Appendix
D). A copy of this research was also provided to each clinic.

CHAPTER IV
Results

Generalized Anxiety Disorder (GAD) is a very common psychiatric disorder in
the United States, affecting upwards of 18% of the population at some point in the
lifespan. The economic impact of anxiety disorders is approximated at $42 billion
annually (Greenberg et al., 1999). Patients with GAD experience detrimental effects in
multiple domains of lite, including occupational, relational, and physical (Weisberg et
al., 2014). There is a magnitude of research to support the use of psychotherapy,
particularly cognitive-behavioral therapy (CBT) and selective serotonin reuptake
inhibitors (SSRIs) as first-line treatment for GAD. However, in practice, the use of
benzodiazepines as first-line and long-term treatment for GAD is widespread (Maust et
al.. 2016). Benzodiazepines, while effective for short-term management of anxiety, can
be associated with many detrimental side effects (especially in the elderly) and cause
dependence when given long-term (Maust et al., 2016). With mounting research
indicating many detrimental side effects with long-term benzodiazepine use. the
Mississippi State Board of Medical Licensure has limited the prescription of
benzodiazepines to 90 days (Mississippi State Board of Medical Licensure, 2018).
The primary goal of this study was to evaluate primary care providers' common
management practices of GAD in primary care settings in northern Mississippi.
Specifically, the research focused on the frequency with which primary care providers
(PCPs) referred GAD patients to psychotherapy, the medications PCPs prescribed for
pharmacological management of GAD. and whether or not the prescription of
benzodiazepines followed the guidelines set forth by the Mississippi State Board of

Medical Licensure. Secondary research questions included the common demographic
characteristics of GAD patients, common demographic traits of patients on long-term
benzodiazepine therapy, and the trends of management of GAD among different PCPs.
A nonexperimental, quantitative, descriptive, retrospective review of charts in
five different primary care clinics in northern Mississippi was conducted to evaluate the
research questions. A convenience sampling of 498 patient charts was used. The
sample included patients 18 years of age or older with a confirmed diagnosis of GAD
F41.1 or Anxiety disorder, unspecified F41.9 that was being addressed during the visit.
Specifically, the provider either wrote a note about the diagnosis, made a referral related
to the diagnosis, or wrote a prescription for the diagnosis. Data collection was limited
to patient records from the year 2014 and forward to the date of data completion—
March 2019. All five primary care clinics utilized electronic health records. The
records were chosen by searching ICD-10 diagnosis codes for either GAD F41.1 or
Anxiety disorder, unspecified F41.9. Patient demographic information obtained during
the data collection included age. gender, race, payer type, and marital status. Additional
information obtained included diagnosis, co-diagnosis, treatment and type of
pharmacological or non-pharmacological, and if referral to psychiatry or psychotherapy
(CBT) was made. If pharmacological treatment included benzodiazepines, the
following was noted; whether or not the provider titrated the medication down and
whether or not the provider educated the patient about the need for titration or cessation
of benzodiazepine treatment. Finally, the provider type was retrieved from the chart.
Although a goal of 500 charts was initially set, eligibility criteria limited the
convenience sample to 498.

Profile of Study Participants
Age. The research sample consisted of individuals ranging from 18 to 88 years
of age. Age of the sample population was grouped into three categories. Group 1
consisted of 92 patients aged 1 8-30 years, group 2 consisted of 313 patients aged 31-64
years, and group 3 consisted of 93 patients 65 years or greater in age.
Gender. The sample population was comprised of more females than males.
Of the records reviewed. 353 (70.9%) were female patients, and 145 (29.1%) were male
patients.
Race. The sample was comprised of 415 (83.3%) Caucasians, 56 (11.2%)
African-Americans, 12 (2.4%) Hispanics, 13 (2.6%) unknown race, 1 (0.2%) Native
American, and 1 (0.2%) other. There were no Asian American or Middle Eastern
patients in the random sample population.
Payer type. The payer type of the sample consisted of 252 (50.6%) with
commercial insurance, 125 (27.1%) with Medicare, 65 (13.1%) self-payer, and 46
(9.2%) with Medicaid.
Marital status. The marital status of the sample was comprised of 272 (54.6%)
married, 115 (23.1%) single, 44 (8.8%) unknown status, 38 (7.6%) divorced, 27 (5.4%)
widowed , and 2 (0.4%) separated.
Provider type. The provider type of the sample was comprised of 321 (64.5%)
patients were treated by a nurse practitioner, 141 (28.3%) were treated by a medical
doctor (MD), 34 (6.8%) were treated by a doctor of osteopathy (DO), and 2 (0.4%)
patients were treated by a physician s assistant (PA).

Diagnosis. The sample population was identified by utilizing ICD-10 diagnosis
codes of GAD F41.1 or Anxiety disorder, unspecified F41.9. Of the sample {N = 498),
376 (75.5 / 0 ) were diagnosed with Anxiety disorder, unspecified F41.9. and 122 (24.5%)
were diagnosed with GAD F41.1.
Co-diagnoses. The current researchers identified six different co-diagnoses
noted in t h e s a m p l e p o p u l a t i o n i n a d d i t i o n t o a n x i e t y d i a g n o s e s . O f t h e t o t a l s a m p l e ( N
= 498). 294 (40.9%) had at least one co-diagnosis. Of those who had a co-diagnosis,
140 (47.6%) had a diagnosis of other as listed on tool, 94 (32.0%) had a diagnosis of
depression. .i0 (10.2%) had a diagnosis of chronic obstructive pulmonary disease
(COPD). 19 (6.5%) had a diagnosis of congestive heart failure (CHF), 6 (2.0%) had a
diagnosis of chronic kidney disease (CKD), and 5 (1.7%) had a diagnosis of
cerebrovascular accident (CVA). Of those identified with a co-diagnosis (n = 294), 28
(9.5%) were identified as having multiple co-diagnoses.
Treatment type. The type of treatment modality for the sample, including
phannacologic and nonpharmacologic, was determined. Of the sample population. 463
(93.0%) patients were treated with phannacological therapy alone, 30 (6.0%) patients
were treated with a combination of phannacologic and nonphannacologic therapy, and
5 (1.0%) patients were treated with nonphannacologic treatment alone.
Nonpharmacologic treatment type.

Of the patients treated with

nonphannacological therapy or a combination therapy ot nonpharmacological and
phannacological therapy, 22 (62.9%) were referred to psychiatry and 9 (25.7%) were
specifically referred for CBT. Within the sample, 4(1.1 /o) of those sampled were
already established patients with psychiatry.

Pharmacologic treatment type. Of the patients treated with pharmacological
therapy, 223 (45.23%) patients were prescribed a SSR1 alone. 105 (21.31%) were
prescribed a benzodiazepine alone, 86 (17.44%) patients were prescribed a combination
ofSSRl and a benzodiazepine, and 79 (16.02%) were prescribed another
pharmacological agent for anxiety. In total, 191 (38.4%) patients were treated with
benzodiazepine therapy, whether alone or in combination with another medication.
Length of benzodiazepine therapy. For patients who were prescribed a
benzodiazepine, either alone or in combination with a SSRI, the length of treatment was
noted. Data were calculated from patients who were prescribed a benzodiazepine only
and from patients who were prescribed a benzodiazepine in combination with another
prescription. From the sample of all patients who were prescribed a benzodiazepine («
= 191). 48 (25.1%) patients were prescribed benzodiazepines for one month or less, 14
(7.3%) were prescribed benzodiazepines for 2 months or less, 35 (18.3%) were
prescribed benzodiazepines for 3 months or less, 94 (49.3%) were prescribed
benzodiazepines for a time period > 3 months.
Education or discussion of titration or cessation of benzodiazepine
treatment. For patients prescribed a benzodiazepine (« = 191). it was noted whether or
not the prescriber discussed titration or cessation of benzodiazepine treatment with the
patient. Of the sample that were prescribed a benzodiazepine. 31(16.2%) were
provided education or discuss,on regarding t,.ration or cessation of benzodiazepines
treatment).
Titration of benzodiazepine treatment. It was noted how many patients were
. , . ,
nf u-trtQP found who were prescribed a benzodiazepine ( n
titrated down in their therapy. Of those tounu wnu
F

191). only 32 (16.8%) of those sampled had documentation of any effort to titrate
down the benzodiazepine.
Statistical Results
A random convenience sampling of 498 medical records was reviewed to
complete this letrospective chart review. In total, 376 patients had a diagnosis of GAD
F41.1 and 122 had a diagnosis of Anxiety disorder, unspecified F41.9. Patients aged 18
years or oldei with either of these diagnoses met the inclusion criteria. The researchers
entered all statistical information from the data collection worksheets into a Microsoft
Excel spreadsheet and formulated to determine n = number for each category.
Inferential statistics were tested using a = 0.05. The researchers investigated the
following research questions:
1. Are PCPs in northern Mississippi referring patients to psychotherapy for
treatment of GAD F41.1 and/or Anxiety disorder, unspecified F41.9?
2. What medications are PCPs prescribing for the treatment of GAD F41.1
and/or Anxiety disorder, unspecified F41.9?
3. If PCPs are prescribing benzodiazepines to their GAD F41.1 and/or Anxiety
disorder, unspecified F41.9 patients, are they limiting prescriptions to three
months?
Research question 1. Are PCPs in northern Mississippi referring patients
to psychotherapy for treatment of GAD? Psychotherapy, specifically CBT, is
effective for long-term management of anxiety; therefore, it was relevant to inquire how
often PCPs utilize this form of treatment. Research supports CBT as first-line treatment
of anxiety to manage symptoms (Weisberg et al., 2014). Literature suggested that when

patients utilize CBT or psychotherapy, the patients reported higher levels of satisfaction
than when pharmacological treatments were used alone (Maust et ah, 2016). Of the
patients identified in the sample population (» = 35) who were referred for
psychotherapy, 26 (74.3%) of these patients were referred to psychiatric services
without a specific modality of treatment, and 9 (25.7%) were specifically referred for
CBT.
Research question 2. What medications are PCPs prescribing for the
treatment of GAD? Research regarding treatment of anxiety indicated that when
pharmacological treatment is necessary, the first-line choice should be SSRIs. These
medications are considered to be effective, non-addictive, and a mild side effect profile.
Benzodiazepines are discouraged in treatment for anxiety due to dependence and
common adverse effects, although they may be prescribed short-term in cases of
debilitating anxiety (Maust et al., 2016). Statistical analysis found that of the patients
receiving pharmacological treatment (n = 493), 223 (45.2%) were prescribed a SSRI.
105 (21.3%) were prescribed a benzodiazepine alone, 86 (17.4%) were prescribed a
combination of a benzodiazepine and a SSRI. and 79 (16.1%) of patients were
prescribed another class of medication for GAD.
Research question 3. If PCPs are prescribing benzodiazepines to their GAD
patients, are they limiting prescriptions to three months. Research supports
limiting benzodiazepines to short-term periods only as needed for debilitating anxiety
while awaiting for SSRIs to achieve therapeutic effect (Weisberg et al., 2014).
Literature review revealed that 6 to 8 weeks' duration of therapy is recommended
(Maust et al.. 2016). The Mississippi State Board of Medical Licensure (2008) allows

up to 90 days of prescription ot benzodiazepines. Statistical analysis revealed that 94
(49.2%) patients who received benzodiazepine therapy for GAD were still being
prescribed benzodiazepines after 3 months.
1 rends among provider type. Of interest to the researchers were the trends of
treatment among the different provider types. Nurse practitioners were the providers
for ,-»21 (64.5%) ot patient charts. The most common treatment modality among nurse
practitioners was to prescribe an SSRI, 146 (45.6%) patient charts. Nurse practitioners
prescribed an alternative pharmacological agent in 60 (18.7%) patient charts. Both an
SSRI and a benzodiazepine were prescribed for 59 (18.4%) patients. Benzodiazepines
alone were prescribed by nurse practitioners in 54 (17.1%) patient charts. Referrals to
psychotherapy were made in 14 (4.4%) patient charts. Combinations of treatment
modalities were used in multiple patients.
MDs were the providers for 141 (28.3%) patient charts. MDs prescribed SSRIs
alone in 69 (48.9%) patients and benzodiazepines alone in 33 (23.4%) patients. MDs
prescribed a combination of a benzodiazepine and a SSRI in 24 (17%) patient charts
and prescribed alternative medication for 15 (10.6%) patients. MDs referred patients to
psychotherapy in 7 (5%) patient charts.
DOs provided care for 6.8% of patient charts reviewed ( n = 34). DOs prescribed
benzodiazepines alone in 16 (47.1%) charts. DOs prescribed SSRIs alone in 9 (26.5/o)
patient charts. DOs prescribed alternative pharmacological treatment in 5 (14.7/o)
charts (/? = 5). DOs prescribed both a SSRI and a benzodiazepine in 4 (1 1.8%) patient
records. DOs referred 1 (2.9%) patient to psychiatry.

PAs piovided care foi 2 (0.4%) patients. PAs prescribed benzodiazepines alone
in 2 (100/o) patient charts. However, the validity for this group was low due to the
small sample size.
Trends among patient demographies. The demographic trends among
patients with anxiety were noted. Research suggested that anxiety disorders are more
prevalent in elderly females, in higher socioeconomic class, and with significant health
comorbidities (Ruscio et al., 2017). From data collected, women in the sample
outnumbered men (/? = 353, 71%). The most common age category {n = 313) was the
31-64-years-old. The most common race was Caucasian (» = 415, 83.3). The most
prevalent payer type, indicating socioeconomic status, was commercial at 252 (50.6%).
The most common marital status was married seen in 272 (54.6%) charts. Codiagnoses among the sample (N = 498) were as follows: 235 (47.2%) did not have any
co-diagnoses, 140 (28.1%) had documentation of a co-diagnoses other than what was
listed on the tool, 94 (18.9%) had depression. 30 (6.0%) had COPD, 19 (3.8%) had
CHF. 6 (1.2%) had CKD . and 4 (0.8%) had CVA. Data also revealed that, of those
sampled with a co-diagnosis listed in the tool, 35 (13.3%) had more than one of the
listed co-diagnoses.
Trends among patients on benzodiazepine therapy. Statistical analysis from
the current research found the following trends among patients receiving
benzodiazepine therapy. The most common age range for patients on benzodiazepine
therapy was in the 31 - to 63-year-old range (« = 121). Women were far more likely to
be on benzodiazepine therapy, comprising 144 (75.4%) patients on the drug. Of the
sample 158 (82.7%) of the patients prescribed a benzodiazepine were Caucasian.

Commercial insurance was the most common payer type among patients on the drug (n
- 82, 42.9 /o). T h e majority of patients o n benzodiazepine therapy were married ( n =
110, 57.6%). Of the 191 patients prescribed benzodiazepines, 494 (9.2%) remained on
a benzodiazepine for > 3 months.

Summary of Findings
Chapter IV presented the researchers" findings from the retrospective review of
498 patient charts from five clinics in northern Mississippi. Findings from the
demographies and research questions were presented. Although benzodiazepines are
typically not first-line treatment in the management of anxiety and are not
recommended for long-term therapy, the researchers found compliance with the
recommendations for treating patients with anxiety were not being followed. Only 36
(7.2%) patients were referred for psychotherapy. PCPs only prescribed SSRIs in less
than half of patients (n = 223, 44.8%) with anxiety. Yet, according to research, these
meds should be used first-line. Benzodiazepines were prescribed for 191 (38.4%)
patients with anxiety. Of the patients prescribed benzodiazepines, 191 (49.2%) were
not limited to the state board prescriptive guidelines of a 90-day timeframe. Among
different types of PCPs. nurse practitioners and MDs were found to have similar
treatment practices. DOs and PAs were found to be the most noncompliant with
evidence-based practice recommendations. Demographic trends among patients with
anxiety diagnoses were consistent with research. Demographic trends among patients
treated with benzodiazepines were also consistent with the literature. These conclusions
supported the need for further provider education regarding appropriate treatment of

anxiety in the primary care setting as well as the opportunity for development of
primar\ caie guidelines to streamline therapy modalities for patients with anxiety.

CHAPTER V
Summary, C onclusions, and Recommendations
The purpose of this study was to evaluate the management practices of anxiety
among primary care providers in northern Mississippi and to evaluate those practices
against the current research. Although there are evidence-based studies supporting the
use ot certain pharmacological and nonpharmacological treatments for the disorder, the
American Psychiatric Association has not published clinical guidelines for PCPs to
follow as of 2018 ("Clinical practice guidelines," 2018). The researchers evaluated how
patients with an anxiety diagnosis by their PCPs were treated and if any guidelines were
followed. It was noted in current literature that although CBT and SSRIs have been
established in research as first-line treatment options for anxiety, many providers
prescribe benzodiazepines long-term for patients.
The design and methodology of the study conducted by the nurse researchers
consisted of a retrospective convenient sampling of approximately 100 charts in five
separate clinics across north Mississippi. Inclusion criteria were patients between the
ages of 18 and older with a diagnosis of GAD and/or Anxiety disorder, unspecified.
The data were collected using a data collection worksheet constructed by the
researchers. Management practices were evaluated by the following research questions.
1. Are PCPs in northern Mississippi referring patients to psychotherapy for
treatment of GAD F41.1 and/'or Anxiety disorder, unspecified F41.9?
2. What medications are PCPs prescribing for the treatment of GAD F41.1 and/or
Anxiety disorder, unspecified F41.9?

3. If PCPs are prescribing benzodiazepines to their GAD F41 .land/or Anxiety
disordei. unspecified F41.9 patients, are they limiting prescriptions to three
months?
This reseaich was guided by previous studies related to benzodiazepine safety,
effectiveness ot psychotherapy, and the prescribing of SSRIs first line for the treatment
of.anxiety. Betty Neuman s systems model was the theoretical framework used to
guide the current research. Some of the major concepts from this model include the
uniqueness of the individual, adaptation to stress, and wholistic wellness promotion.
Due to these major concepts, the systems model is frequently used to guide nursing
research related to psychological stress or dysfunction. Neuman wrote about four major
assumptions pertinent to the application of the model: person, environment, health, and
nursing.
Summary of the Findings
The sample project consisted of 498 patient records. The samples were gathered
from five primary care clinics in North Mississippi during March 2019. All 498 patient
records either had a diagnosis of GAD F41.1 or Anxiety disorder, unspecified F41.9.
Of the total records reviewed, 353 (70.9%) were female patients and 145 (29.1%) were
male patients. Ages were grouped into three different categories, 18-30, 31-64, and >65
years old. Of all the records reviewed, 92 (18.5) were in the 18-30 year old category,
313 (62.9%) were in the 31- to 64-year-old category, 93 (18.7%) were in the > 65-yearold category. Ethnicity of the sample consisted of 415 (83%) Caucasians, 56 (11.2%)
African Americans, 12 (2.4%) Hispanics, 1 (0.2%) Native American, 1 (0.2%) Other,
and 13 (2.6%) Not Specified. There were no Middle Eastern or Asian Americans in the

sample population. I he sample showed a variety of payment methods including
Commercial Insurance (n = 252. 50.6%), Medicare (n = 135. 27.1%), Self-Payer (n =
65, 13.1 /o), and Medicaid (/; = 46, 9.2%). Patient records were pulled from a variety of
providers including Nurse Practitioners (/? = 321. 64.5%), Medical Doctors (/; = 141,
28.3%), Doctors of Osteopathic Medicine (n = 34, 6.8%). and Physician Assistants (n =
2, 0.4%).
According to the review of literature, providers should utilize psychotherapy as
first-line treatment for anxiety; if unsuccessful, a SSRI should be prescribed.
Benzodiazepine prescription should only be used short-term and as an adjunct to other
therapy. Of the patients diagnosed with either GAD F41.1 or Anxiety disorder,
unspecified F41.9, 463 (93%) received a phannacological treatment type, 30 (6%)
received both pharmacological and nonpharmacological treatment type, and 5 (1%)
received a nonpharmacological treatment type alone. SSRIs were prescribed in 223
(44.8%) charts, 86 (1 7.3%) were prescribed SSRI and benzodiazepines together, and
another agent was used in 15.9% (n = 79) of charts. In total, 191 (38.4%) were
prescribed benzodiazepines, whether alone or in combination with another medication.
Discussion of Findings

According to the review of literature, benzodiazepines should not be used for the
primary treatment of anxiety, yet data showed that 21.1% (» = 105) of the time it was
used as a first-line medication. When accounting for benzodiazepines prescribed in
combination with other medications, 191 (38.4%) patients received a benzodiazepine
prescription. The current researchers also found that the majority of the patients
prescribed benzodiazepines were married (« = 272, 54.6%). females (« = 353, 70.9%),

and Caucasian („ = 415, 83.3%). According to the review of literature, a
benzodiazepine may only be used as an adjunct to therapy or in a short-term duration of
therapy. From the sample o t all patients who were prescribed a benzodiazepine (n =
191). 48 (25.1%) were prescribed benzodiazepines for one month or less. 14 (7.3%),
were prescribed benzodiazepines for 2 months or less, 35 (18.3% ) were prescribed
benzodiazepines tor 3 months or less, and 94 (49.3%) were prescribed benzodiazepines
for a time period > 3 months.
Our research findings indicated that the only providers who prescribed
nonpharmacological treatment alone were nurse practitioners, seen in only 5 (1%) of
patients. The other providers (e.g., MDs, DOs, and PAs) did not prescribe
nonpharmacological treatment alone. It should also be noted that 30 (6%) patients
received psychotherapy in combination with pharmacological therapy. These results
are in sharp contrast to literature suggesting that patients receive psychotherapy as firstline treatment for GAD (Landreville et al., 2016).
SSRIs were prescribed alone in 223 (44.8%) patient charts reviewed.
Benzodiazepines were prescribed as a single treatment modality in 105 (21.1%) cases.
Both a benzodiazepine and a SSRI were given in 86 (17.3%) cases. The gender
distribution was 350 (70.9%) females and 145 (29.1%) males. It appears that women
are more likely to seek treatment for anxiety. Our research findings revealed the age
group that was most frequently seen for anxiety were aged from 31-64 years old (n =
313 62 9%) These findings were consistent with research that correlated an anxiety
diagnosis with females and ages < 60-years (Ruscio et al., 2017).

Limitations

Limitations readily identifiable prior to performing data collection were
identified as small sample size, geographically limited data collection, and the use of
convenience sampling. As recognized in the methodology section of this study, data
were obtained by performing a retrospective chart review from five primary care clinics
in northern Mississippi. The population consisted of adults aged 18 years and older.
Data were collected and analyzed from a sample of 498 charts. The study was designed
to examine the management practices of primary care providers in the treatment of
GAD F41.1 or Anxiety disorder, unspecified F41.9.
The researchers identified several limitations that had the potential to modify the
outcomes of the study. Data were collected via convenience sample, thus
randomization was limited. Convenience sampling does not provide a true
representation of the entire population because the participants were chosen simply out
of convenience by the researchers. Also, two significant limitations were the small
sample size and the short duration of data collection. Of the 500 charts viewed, the
sample size consisted of 498 charts that met requirements. This small size limited
generalizability of the findings and reliability of study results. Additionally, data
collection only occurred for one month (March of 2019), thus limiting time for data
collection.
Regarding provider type, the small sample of 2 PAs and 34 DOs limited
generalizability of data to a broader provider population. Another limitation was found
with the marital status category on the tool. In practice, it appears that this demographic
is updated infrequently and may be unreliable. The data worksheet concerning

comorbidities proved to be a limitation. Some researchers coded all eligible comorbid
conditions for each patient, while some researchers elected to code only one
comorbidity. 1 his discrepancy among the researchers resulted in inconclusive data
regarding comorbidities among patients with anxiety.
Another limitation was the wide variety of formats of patients" charts that were
reviewed for data collection. While some charts had a specific location at which to find
information regarding the research questions, some charts had a less clear format so
there is a possibility that pertinent data could have been overlooked.
In regard to geographic diversity, all data were collected in clinics within a 29mile perimeter. Therefore, findings only represented a small portion of one state and
may not be appropriate for generalization beyond this geographic location.
Conclusions
The purpose of this study was to determine management practices of primary
care providers in the treatment of anxiety in northern Mississippi. The study evaluated
the charts of patients 18 years of age and older. The study design was a retrospective
chart review of 498 charts that were selected based on a diagnosis of GAD F41.1 or
Anxiety disorder, unspecified F41.9. Based on the current research data, nurse
practitioners were the only provider type that prescribed nonphannacological treatment
for anxiety. MDs and nurse practitioners were less liberal in benzodiazepine
prescription practices; however, the sample sizes for PAs and DOs were limited. There
were only 34 DOs and 2 PAs in the sample. When comparing the providers in the
current research, NPs were found to be the only providers that referred to
psychotherapy. Based on research data, the majority of primary care providers in

Mississippi were prescribing pharmacological therapy as first-line treatment for anxiety.
It is plausible that the primary care providers were not aware of research-based
recommendations when prescribing benzodiazepines. The researchers concluded that
primary care providers in Mississippi demonstrate a need for heightened awareness and
education regarding research-based recommendations for prescribing benzodiazepines.
Implications

Long-term benzodiazepine usage is present among patients with anxiety despite
known harmful effects of the drug class and the availability of more effective treatments
(Bernard et ah, 2018). The problem has gained attention of multiple federal and state
agencies. Research regarding the harmful effects of benzodiazepines and the
availability of more effective treatment options for anxiety have led the Mississippi
Board of Medicine to adopt restrictions on benzodiazepine prescription to 90 days
(Mississippi State Board of Medical Licensure, 2018).
Previous research has suggested other interventions through using the electronic
health record. Some of these interventions previously studied are as follows. One
suggested alternative intervention provided a pop-up screen for each patient diagnosed
with GAD F41.1 or Anxiety disorder, unspecified F41.9, stating that benzodiazepines
are not generally indicated for a certain diagnosis. The medical record would then
suggest alternative treatment options for the patient. This intervention would remind
the primary care providers that alternative interventions besides prescribing
benzodiazepines could be utilized. The accountable justification intervention prompted
the providers while in the EHR by asking them to free text their treatment decision if a
benzodiazepine was prescribed for a diagnosis of GAD and/or Anxtety disorder.

unspecified. The prompt would not be dismissed unless the provider acknowledged it.
but the provider could dismiss the benzodiazepine order which would not create a
justification note. The behavioral intervention would improve providers' decision
making about inappropriate benzodiazepine-prescribing. The peer comparison
intervention would allow providers to be ranked from the most to least in appropriate
benzodiazepine prescribing using the EHR data. The providers with the lowest rates of
inappropriate benzodiazepine prescribing would receive an email each month stating
they were the " \ op Performers." 1 he remaining providers of inappropriate
benzodiazepine prescribing would receive an email each month stating that they were
"Not a I op Performer.

1 he emails included the amount of prescribed benzodiazepines

that were inappropriate for GAD and/or Anxiety disorder, unspecified compared to
those listed by top performers.
The research identified that the utilization of psychotherapy was very low
among all providers. Research indicated that psychotherapy should be a first-line
intervention as well as an adjuvant to all anxiety disorder treatments. It appears that all
types of providers need more education regarding the utilization of psychotherapy in the
treatment of anxiety disorders in order to comply with research-based
recommendations.
These interventions may be helpful in improving adherence to the short-term use
of benzodiazepine therapy. Decreasing the number of benzodiazepine prescriptions
written will help to decrease the overuse that is leading to the benzodiazepine crisis.
This research project yielded findings

that PCPs in northern Mississippi employ

practices of benzodiazepine prescription that are somewhat incongruent with research-

based recommendations. The implication is that nonadherence to the standards of care
continue to place patients at risk for benzodiazepine addiction and abuse.
Recommendations
The student researchers revealed during the study that multiple areas of interest
warrant further investigation through future research. Four recommendations were
created from this study. First, replication of the study should indicate a larger sample
size to ensure a more accurate representation of healthcare provider practices for the
GAD and/or Anxiety disorder, unspecified population. Second, replication of the study
should include a more populous sample ascertained by including a more extensive
geographical area. Third, replication of the study should include less time constraints
allowing for an extended period of time. Fourth, any future study should correct the
limitations as described above.
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APPENDIX A
Retrospective Chart Review Data Collection Tool

Age in years

18-30

31-64

65+

Gender

vlale

-emale

Other

Race

Caucasian

AfricanAmerican

Hispanic

Asian
American

Middle
Eastern

Payer type

Commercial

Medicaid

Medicare

Self-payer

Other

Marital
status
Provider
type
Diagnosis

Single

Married

Divorced

Widowed

Separated

Other

NP

MD

DO

PA

Generalized
Anxiety
Disorder F41.1
CHE

Anxiety,
unspeci
fied F41.9
COPD

CKD

Depression

CVA

Other

Pharmacologic

Nonpharmacologic
SSRI

Both

Both

Other

1 month or
less

2 months
or less

3 months or
less

>3
months

Education or
discussion
regarding
titration or
cessation of
benzodiaze
pine

Yes

No

Titration
down or
cessation of
benzodiaze
pine
treatment
If nonpharmacologic
treatment,
what type

Yes

No

CBT

Referral to
psy
chiatric
services

Codiagnosis
Treatment

If pharmaco
logic
treatment,
what
medication
How long
benzoiazepine
treatment

Benzodiaze
pine

Mative
Americ
an

Other
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APPENDIX C
Consent to Conduct Study
To Whom It May Concern:
We are graduate students in the Family Nurse Practitioner program at Mississippi
University tor Women in Columbus, Mississippi. As a program requirement, we are
conducting a study to evaluate Generalized Anxiety Disorder (GAD) management
practices among primary care providers in northern Mississippi. We will be conducting
a retrospective chart review of patients between the ages of 18 and 100 years old with a
diagnosis of GAD or anxiety. We are requesting permission to review eligible charts of
patients in your clinic. We are aware that we will need to maintain confidentiality of all
infonnation obtained.
We agree to undergo or consent to any HIPPA requirements set forth by your practice
regarding patient privacy and confidentiality. The data collected from each review will
be recorded on a data collection worksheet to be kept on a confidential electronic flash
drive stored in a secure location with access only to the researchers. At termination of
research project, this infonnation will be destroyed by incineration of the drive per
HIPPA guidelines. No clinic or patient identifiers will be used in the study.
Your participation in this study is strictly voluntary. You may withdraw your consent
and participation in this study at any time. The result of the study will be made
available to you upon completion of the research project.
If you have any questions concerning this study, please contact the following committee
members: Dr. Sueanne Davidson, Committee Chair, 662-329-7323; Grace Henson, 662316-2546; Benjamin Spencer. 662-586-8994; A1 Rayburn, 662-488-5658; Sabrina
McClain, 662-509-0303; or Jennifer Bolen, 662-401-0660.
Sincerely,
Grace Henson, Benjamin Spencer, A1 Rayburn, Sabrina McClain, and Jennifer Bolen

I have read the above letter of consent and agree to the utilization of this clinic for the
above mentioned research project. I understand that HIPPA regulations will be stiict y
followed, and the confidentiality of each chart chosen will be maintained. I also
understand that the results of the study will be made available to me at the pioject s en

Name and Title

Signature

